A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
An immunolglobulin light chain-like protein composed of an IMMUNOGLOBULIN VARIABLE REGION-like peptide (such as light chain like lambda5 peptide) and an IMMUNOGLOBULIN CONSTANT REGION-like peptide (such as Vpreb1 peptide). Surrogate light chains associate with MU IMMUNOGLOBULIN HEAVY CHAINS in place of a conventional immunoglobulin light chains to form pre-B cell receptors.
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
A general term for various neoplastic diseases of the lymphoid tissue.
Lymphocyte progenitor cells that are restricted in their differentiation potential to the B lymphocyte lineage. The pro-B cell stage of B lymphocyte development precedes the pre-B cell stage.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Membrane proteins in precursor B-LYMPHOCYTES (pre-B Cells). They are composed of membrane-bound MU IMMUNOGLOBULIN HEAVY CHAINS in complex with SURROGATE LIGHT CHAINS instead of conventional IMMUNOGLOBULIN LIGHT CHAINS. Only successful rearrangement of the VDJ segments, at the Ig heavy chain gene locus (IMMUNOGLOBULIN HEAVY CHAIN GENES), will generate mu heavy chains that can pair with surrogate light chains. Thus formation of the pre-B cell receptors is an important checkpoint in the development of mature B cells.
A classification of B-lymphocytes based on structurally or functionally different populations of cells.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
The class of heavy chains found in IMMUNOGLOBULIN M. They have a molecular weight of approximately 72 kDa and they contain about 57 amino acid residues arranged in five domains and have more oligosaccharide branches and a higher carbohydrate content than the heavy chains of IMMUNOGLOBULIN G.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.
Progenitor cells from which all blood cells derive.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.
Genes encoding the different subunits of the IMMUNOGLOBULINS, for example the IMMUNOGLOBULIN LIGHT CHAIN GENES and the IMMUNOGLOBULIN HEAVY CHAIN GENES. The heavy and light immunoglobulin genes are present as gene segments in the germline cells. The completed genes are created when the segments are shuffled and assembled (B-LYMPHOCYTE GENE REARRANGEMENT) during B-LYMPHOCYTE maturation. The gene segments of the human light and heavy chain germline genes are symbolized V (variable), J (joining) and C (constant). The heavy chain germline genes have an additional segment D (diversity).
A cytokine produced by bone marrow stromal cells that promotes the growth of B-LYMPHOCYTE precursors and is co-mitogenic with INTERLEUKIN-2 for mature T-LYMPHOCYTE activation.
An immunologic deficiency state characterized by an extremely low level of generally all classes of gamma-globulin in the blood.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
One of the types of light chain subunits of the immunoglobulins with a molecular weight of approximately 22 kDa.
A subclass of IMIDES with the general structure of pyrrolidinedione. They are prepared by the distillation of ammonium succinate. They are sweet-tasting compounds that are used as chemical intermediates and plant growth stimulants.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC).
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Ordered rearrangement of B-lymphocyte variable gene regions coding for the IMMUNOGLOBULIN CHAINS, thereby contributing to antibody diversity. It occurs during the differentiation of the IMMATURE B-LYMPHOCYTES.
Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.
A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Mapping of the KARYOTYPE of a cell.
Ordered rearrangement of B-lymphocyte variable gene regions coding for the kappa or lambda IMMUNOGLOBULIN LIGHT CHAINS, thereby contributing to antibody diversity. It occurs during the second stage of differentiation of the IMMATURE B-LYMPHOCYTES.
The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.
A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).
A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
Infections caused by the HTLV or BLV deltaretroviruses. They include human T-cell leukemia-lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED).
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The return of a sign, symptom, or disease after a remission.
A transcription factor that dimerizes with the cofactor CORE BINDING FACTOR BETA SUBUNIT to form core binding factor. It contains a highly conserved DNA-binding domain known as the runt domain. Runx1 is frequently mutated in human LEUKEMIAS.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
A notch receptor that interacts with a variety of ligands and regulates SIGNAL TRANSDUCTION PATHWAYS for multiple cellular processes. It is widely expressed during EMBRYOGENESIS and is essential for EMBRYONIC DEVELOPMENT.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Species of GAMMARETROVIRUS, containing many well-defined strains, producing leukemia in mice. Disease is commonly induced by injecting filtrates of propagable tumors into newborn mice.
A cell line derived from cultured tumor cells.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.
That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.
A genus in the family RETROVIRIDAE consisting of exogenous horizontally-transmitted viruses found in a few groups of mammals. Infections caused by these viruses include human B- or adult T-cell leukemia/lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), and bovine leukemia (ENZOOTIC BOVINE LEUKOSIS). The type species is LEUKEMIA VIRUS, BOVINE.
Transcriptional trans-acting proteins of the promoter elements found in the long terminal repeats (LTR) of HUMAN T-LYMPHOTROPIC VIRUS 1 and HUMAN T-LYMPHOTROPIC VIRUS 2. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the LTR.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Antibodies produced by a single clone of cells.
Established cell cultures that have the potential to propagate indefinitely.
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
B-cell lymphoid tumors that occur in association with AIDS. Patients often present with an advanced stage of disease and highly malignant subtypes including BURKITT LYMPHOMA; IMMUNOBLASTIC LARGE-CELL LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; and DIFFUSE, LARGE B-CELL, LYMPHOMA. The tumors are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in AIDS is a complex result of EBV infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.
Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.
DNA present in neoplastic tissue.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
A transcription factor that plays a role as a key regulator of HEMATOPOIESIS. Aberrant Ikaros expression has been associated with LYMPHOBLASTIC LEUKEMIA.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin.
Differentiation antigens expressed on pluripotential hematopoietic cells, most human thymocytes, and a major subset of peripheral blood T-lymphocytes. They have been implicated in integrin-mediated cellular adhesion and as signalling receptors on T-cells.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.

Signal transduction triggered by lipid A-like molecules in 70Z/3 pre-B lymphocyte tumor cells. (1/390)

The lipid A (endotoxin) moiety of lipopolysaccharide (LPS) elicits rapid cellular responses from many cell types, including macrophages, lymphocytes, and monocytes. In CD14 transfected 70Z/3 pre-B lymphocyte tumor cells, these responses include activation of the MAP kinase homolog, p38, activation of NF-kappaB, and transcription of kappa light chains, leading to the assembly of surface IgM. In this work, we explored the specificity of the response with regard to lipid structure, and the requirement for p38 kinase activity prior to NF-kappaB activation in control and CD14 transfected 70Z/3 (CD14-70Z/3) cells. A p38-specific inhibitor, SB203580, was used to block p38 kinase activity in cells. CD14-70Z/3 cells were incubated with 1-50 microM SB203580, and then stimulated with LPS. Nuclear extracts were prepared, and NF-kappaB activation was measured using an electrophoretic mobility shift assay. SB203580 did not inhibit LPS induced NF-kappaB activation. In addition, LPS failed to activate p38 tyrosine phosphorylation in 70Z/3 cells lacking CD14, in spite of rapid NF-kappaB activation and robust surface IgM production with appropriate higher doses of LPS. LPS stimulation of p38 phosphorylation, NF-kappaB activation, and surface IgM expression were all blocked completely by lipid A-like endotoxin antagonists whether or not CD14 was present. Acidic glycerophospholipids and ceramides did not mimic lipid A-like molecules either as agonists or antagonists in this system. Our data support the hypothesis that lipid A-mediated activation of cells requires stimulation of a putative lipid A sensor that is downstream of CD14, but upstream of p38 and NF-kappaB.  (+info)

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. (2/390)

PURPOSE: Rituximab was recently approved for use in relapsed, low-grade non-Hodgkin's lymphoma; however, few data exist regarding the safety of this agent in patients with a high number of tumor cells in the blood. METHODS AND RESULTS: After the observation at our institution of a rapid reduction of peripheral-blood tumor cells with associated severe pulmonary infusion-related toxicity in two patients with refractory hematologic malignancies, data on three additional cases were collected from physician-submitted reports of adverse events related to rituximab treatment. Five patients with hematologic malignancies possessing a high number of blood tumor cells were treated with rituximab and developed rapid tumor clearance. The median age was 68 years (range, 26 to 78 years). Patients were diagnosed with B-cell prolymphocytic leukemia (n = 2), chronic lymphocytic leukemia (n = 2), or transformed non-Hodgkin's lymphoma (n = 1). All of these patients had bulky adenopathy or organomegaly. All five patients developed a unique syndrome of severe infusion-related reactions, thrombocytopenia, rapid decrement in circulating tumor cell load, and mild electrolyte evidence of tumor lysis, and all required hospitalization. In addition, one patient developed ascites. These events resolved, and four patients were subsequently treated with rituximab without significant complications. CONCLUSION: Rituximab administration in patients who have a high number of tumor cells in the blood may have an increased likelihood of severe initial infusion-related reactions. These data also suggest that rituximab may have activity in a variety of other lymphoid neoplasms, such as chronic lymphocytic leukemia and B-cell prolymphocytic leukemia.  (+info)

Inhibition of caspases inhibits the release of apoptotic bodies: Bcl-2 inhibits the initiation of formation of apoptotic bodies in chemotherapeutic agent-induced apoptosis. (3/390)

During apoptosis, the cell actively dismantles itself and reduces cell size by the formation and pinching off of portions of cytoplasm and nucleus as "apoptotic bodies." We have combined our previously established quantitative assay relating the amount of release of [3H]-membrane lipid to the degree of apoptosis with electron microscopy (EM) at a series of timepoints to study apoptosis of lymphoid cells exposed to vincristine or etoposide. We find that the [3H]-membrane lipid release assay correlates well with EM studies showing the formation and release of apoptotic bodies and cell death, and both processes are regulated in parallel by inducers or inhibitors of apoptosis. Overexpression of Bcl-2 or inhibition of caspases by DEVD inhibited equally well the activation of caspases as indicated by PARP cleavage. They also inhibited [3H]-membrane lipid release and release of apoptotic bodies. EM showed that cells overexpressing Bcl-2 displayed near-normal morphology and viability in response to vincristine or etoposide. In contrast, DEVD did not prevent cell death. Although DEVD inhibited the chromatin condensation, PARP cleavage, release of apoptotic bodies, and release of labeled lipid, DEVD-treated cells showed accumulation of heterogeneous vesicles trapped in the condensed cytoplasm. These results suggest that inhibition of caspases arrested the maturation and release of apoptotic bodies. Our results also imply that Bcl-2 regulates processes in addition to caspase activation.  (+info)

The human (PsiL+mu-) proB complex: cell surface expression and biochemical structure of a putative transducing receptor. (4/390)

The surrogate light chain (PsiL) associates with mu and Igalpha-Igbeta chains to form the preB-cell receptor that plays a critical role in early B-cell differentiation. Discrepancies exist in human concerning the existence of PsiL+mu- proB cells and the biochemical structure of such a proB-cell complex remains elusive. Among new antihuman VpreB monoclonal antibodies (MoAbs), 5 of the gamma kappa isotype bound to recombinant and native VpreB protein with high affinity. They recognized 4 discrete epitopes, upon which 2 were in the extra-loop fragment. Such MoAbs detected the PsiL at the cell surface of either preB or on both proB and preB cells. The previously reported SLC1/SLC2 MoAbs recognize a conformational epitope specific for the mu/PsiL association in accordance with their preB-cell reactivity. Using the proB/preB 4G7 MoAb, PsiL cell surface expression was detected on normal bone marrow, not only on CD34(-)CD19(+) preB but also on CD34(+)CD19(+) proB cells. Futhermore, this MoAb identified PsiL+mu- fresh proB leukemic cells of the TEL/AML1 type. Biochemical studies showed that, at the proB stage, the PsiL is associated noncovalently with two proteins of 105 and 130 kD. Triggering of this complex induces intracellular Ca2+ flux, suggesting that the PsiL may be involved in a new receptor at this early step of the B-cell differentiation.  (+info)

Bone marrow pre-B-1 (Bomb1): a quantitative trait locus inducing bone marrow pre-B-cell expansion in lymphoma-prone SL/Kh mice. (5/390)

Abnormalities of regulatory genes in early B-cell development often lead to lymphomagenesis. Our previous study showed that there is an abnormal transient expansion of bone marrow (BM) pre-B cells in lymphoma-prone SL/Kh strain mice. Such expansion is a genetic property of SL/Kh stem cells rather than BM microenvironments. Using the percentage of BP1+ B220+ pre-B cells in total BM lymphoid cells as a quantitative parameter, we studied the genetic control of BM pre-B cells in 159 F2 offspring of crosses between SL/Kh and NFS/N mice and 334 back-crosses to SL/Kh mice. A highly significant quantitative trait locus was identified on the distal segment of chromosome 3, showing logarithm of odds scores of 22.7 in the F2 cohort and 10.7 in back-cross mice. This quantitative trait locus, named bone marrow pre-B-1, colocalized with lymphoid enhancer factor-1, which encodes a high mobility group DNA-binding protein that is expressed in T and pre-B cells.  (+info)

Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia. (6/390)

Genetic and environmental factors play an interactive role in the development of childhood acute lymphoblastic leukemia (ALL). Since the demonstration of a major histocompatibility complex (MHC) influence on mouse leukemia in 1964, an HLA association has been considered as a possible genetic risk factor. Despite extensive efforts, however, no strong evidence comparable to the H-2(k) influence on mouse leukemia has been shown. The number of negative serological studies resulted in a loss of interest and consequently, no molecular HLA-DR association study has been published to date. We reconsidered the HLA-DR association in childhood ALL in 114 patients from a single center and 325 local newborn controls by polymerase chain reaction (PCR) analysis of the HLA-DRB1/3/4/5 loci. With conventional analysis, there was a moderate allelic association with the most common allele in the HLA-DR53 group, HLA-DRB1*04, in the whole group that was stronger in males (P =.0005, odds ratio = 2.9). When the other expressed HLA-DRB loci were examined, homozygosity for HLA-DRB4*01, encoding the HLA-DR53 specificity, was increased in patients (21.1% v 8.3%; odds ratio = 2.9, P =.0005). Consideration of gender showed that all of these associations were reflections of a male-specific increase in homozygosity for HLA-DRB4*01 (32.8% v 4. 0%; odds ratio = 11.7, 95% confidence interval [CI] = 4.9 to 28.0; P = 3 x 10(-8)). This highly significant result provided the long-suspected evidence for the HLA-DR influence on the development of childhood ALL while confirming the recessive nature of the MHC influence on human leukemogenesis as in experimental models. The cross-reactivity between HLA-DR53 and H-2Ek, extensive mimicry of the immunodominant epitope of HLA-DR53 by several carcinogenic viruses, and the extra amount of DNA in the vicinity of the HLA-DRB4 gene argue for the case that HLA-DRB4*01 may be one of the genetic risk factors for childhood ALL.  (+info)

High frequency of adhesion defects in B-lineage acute lymphoblastic leukemia. (7/390)

Aberrant proliferation, differentiation, and/or migration of progenitors observed in various hematological malignancies may be caused by defects in expression and/or function of integrins. In this study, we have developed a new fluorescent beads adhesion assay that facilitates flow cytometric investigation of lymphocyte function-associated antigen 1 (LFA-1)- and very late activation antigen-4 (VLA-4)-mediated functional adhesion in B-lineage acute lymphoblastic leukemia (ALL) of both the CD10(-) and CD10(+) (leukemic) cell population within one blood or bone marrow sample. Surprisingly, of the 20 B-lineage ALL patients investigated, 17 contained a leukemic cell population with LFA-1- and/or VLA-4-mediated adhesion defects. Five patients contained CD10(+) cells that did not exhibit any LFA-1-mediated adhesion due to the lack of LFA-1 surface expression. The CD10(+) cells from 10 ALL patients expressed LFA-1 that could not be activated by the phorbol ester phorbol 12-myristate 13-acetate (PMA), whereas the CD10(-) cells expressed a functional LFA-1. Seven patients contained CD10(+) cells that expressed a PMA-unresponsive form of VLA-4. The PMA unresponsiveness of the integrins LFA-1 and VLA-4 expressed by the CD10(+) cells may be due to mutations in the integrins itself, in protein kinases, or in other intracellular molecules involved in integrin adhesion. These data clearly demonstrate the importance of investigating integrin function in addition to integrin surface expression. The strikingly high frequency (85%) of adhesion defects in ALL could suggest a causal relationship between integrin-mediated adhesion and B-lineage ALL.  (+info)

A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells. (8/390)

Some chromosomal translocations involved in the origin of leukemias and lymphomas are due to malfunctions of the recombinatorial machinery of immunoglobulin and T-cell receptor-genes. This mechanism has also been proposed for translocations t(4;11)(q21;q23), which are regularly associated with acute pro-B cell leukemias in early childhood. Here, reciprocal chromosomal breakpoints in primary biopsy material of fourteen t(4;11)-leukemia patients were analysed. In all cases, duplications, deletions and inversions of less than a few hundred nucleotides indicative of malfunctioning DNA repair mechanisms were observed. We concluded that these translocation events were initiated by several DNA strand breaks on both participating chromosomes and subsequent DNA repair by 'error-prone-repair' mechanisms, but not by the action of recombinases of the immune system.  (+info)

Karyotype analysis of acute lymphoblastic leukemia (ALL) at diagnosis has provided valuable prognostic markers for treatment stratification. However, reports of cytogenetic studies of relapsed ALL samples are limited. We compared the karyotypes from 436 nonselected B-cell precursor ALL patients at initial diagnosis and of 76 patients at first relapse. We noticed a relative increase of karyotypes that did not fall into the classic ALL cytogenetic subgroups (high hyperdiploidy, t(12;21), t(9;22), 11q23, t(1;19), ,45 chromosomes) in a group of 29 patients at relapse (38%) compared to 130 patients at presentation (30%). Non-classical cytogenetic aberrations in these 29 patients were mostly found on chromosomes 1, 2, 7, 9, 13, 14, and 17. We also describe six rare reciprocal translocations, three of which involved 14q32. The most frequent abnormalities were found in 9p (12/29 cases) and were associated with a marked decrease in the duration of the second remission, but not of the probability of ...
We identified a novel fusion gene, BMP2K-ZNF384, in addition to the previously reported ZNF384-related fusion genes, including TCF3-, TAF15-, EWSR-, EP300-, CREBBP-, SYNRG-, and ARID1B-ZNF384, and thus 8 fusion partners for the ZNF384 gene have been identified so far.9-15,19-22 Considering the current condition, whereby the frequency of B-others in which specific cytogenetic abnormalities are not present are markedly decreasing, the incidence of ZNF384-related fusion genes in our cohort was unexpectedly high. In the literature, 8 ALL patients with TAF15-ZNF384 have been reported.9,19-21 Similarly, 2 and 3 ALL patients with EWSR1- and TCF3-ZNF384, respectively, have also been described previously.9-10,20-22 Because 6 out of 13 patients in the literature are adults (,21 years), this is the first report on the high frequency of the recurrence of ZNF384-related fusion genes in childhood BCP-ALL in a single nation. It is possible that the differences in the outbreak frequency of ZNF384-related ...
In a few cases, unexpected PCR/FISH-results in sorted cell populations were found; in 2 BM samples (from 2 patients) sorted presumed malignant cells showed discrepant PCR/FISH-negative results, and in 2 BM samples (from 2 patients) PCR-positive cells were detected among sorted presumed normal cells. These 4 cases were carefully reviewed in order to search for explanations and to evaluate the impact on the MRD estimate (Figure 2, Online Supplementary Appendix and Table S2). Possible explanations for the observed discrepancies were: a) only partly informative immunophenotypes at diagnosis resulting in MRD underestimation; b) antigen modulation; c) high number of plasma cells in patients with CD10neg/CD20neg ALL; and d) dead cells in diagonal regions.. A discrepant case with heterogeneous LAIP (CD34broad) at diagnosis emphasizes the importance of defining whether the FC-markers are fully informative (Figure 2A). Another discrepant case was possible due to significant CD10 downmodulation and CD20 ...
Despite risk-adapted treatment, survival of children with relapse of acute lymphoblastic leukemia (ALL) remains poor compared with that of patients with initial diagnosis of ALL. Leukemia-associated genetic alterations may provide novel prognostic factors to refine present relapse treatment strategies. Therefore, we investigated the clinical relevance of 13 recurrent genetic alterations in 204 children treated uniformly for relapsed B-cell precursor ALL according to the ALL-REZ BFM 2002 protocol. The most common alterations were deletions of CDKN2A/2B, IKZF1, PAX5, ETV6, fusion of ETV6-RUNX1 and deletions and/or mutations of TP53. Multivariate analysis identified IKZF1 deletion and TP53 alteration as independent predictors of inferior outcome (P=0.002 and P=0.001). Next, we investigated how both alterations can improve the established risk stratification in relapsed ALL. Intermediate-risk relapse patients with low minimal residual disease are currently considered to have a good prognosis. In ...
Curcumin, a polyphenolic compound isolated from the rhizomes of an herbaceous perennial plant, Curcuma longa, is known to possess anticancerous activity. However, the mechanism of apoptosis induction in cancers differs. In this study, we have (1) investigated the anticancerous activity of curcumin on REH and RS4;11 leukemia cells and (2) studied the chemo-sensitizing potential of curcumin for doxorubicin, a drug presently used for leukemia treatment. It was found that curcumin induced a dose dependent decrease in cell viability because of apoptosis induction as visualized by annexin V-FITC/ PI staining. Curcumin-induced apoptosis of leukemia cells was mediated by PARP-1 cleavage. An increased level of caspase-3, apoptosis inducing factor (AIF), cleaved PARP-1 and decreased level of Bcl2 was observed in leukemia cells after 24h of curcumin treatment. In addition, curcumin at doses lower than the IC50 value signi cantly enhanced doxorubicin induced cell death. Therefore, we conclude that curcumin induces
Järviaho T, Bang B, Zachariadis V, Taylan F, Moilanen J, Möttönen M, Smith CIE, Harila-Saari A, Niinimäki R, Nordgren A Blood Adv 3 (18) 2722-2731 [2019-09-24; online 2019-09-15] Pathogenic germline variants in ETV6 have been associated with familial predisposition to thrombocytopenia and hematological malignancies, predominantly childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In addition, overrepresentation of a high hyperdiploid subtype and older age at diagnosis have been reported among sporadic BCP-ALL cases with germline variants in ETV6 We studied a family with 2 second-degree relatives who developed childhood high hyperdiploid BCP-ALL at ages 8 and 12 years, respectively. A constitutional balanced reciprocal translocation t(12;14)(p13.2;q23.1) was discovered in both patients by routine karyotyping at diagnosis and, subsequently, in 7 healthy family members who had not experienced hematological malignancies. No carriers had thrombocytopenia. Whole-genome sequencing ...
Blood. 2013 Mar 7;121(10):1814-8. doi: 10.1182/blood-2012-01-406272. Epub 2013 Jan 14. Research Support, N.I.H., Extramural; Research Support, Non-U.S. Govt
Fusion genes are potent driver mutations in cancer. In this study, we delineate the fusion gene landscape in a consecutive series of 195 paediatric B-cell precursor acute lymphoblastic leukaemia (BCP ALL). Using RNA sequencing, we find in-frame fusion genes in 127 (65%) cases, including 27 novel fusions. We describe a subtype characterized by recurrent IGH-DUX4 or ERG-DUX4 fusions, representing 4% of cases, leading to overexpression of DUX4 and frequently co-occurring with intragenic ERG deletions. Furthermore, we identify a subtype characterized by an ETV6-RUNX1-like gene-expression profile and coexisting ETV6 and IKZF1 alterations. Thus, this study provides a detailed overview of fusion genes in paediatric BCP ALL and adds new pathogenetic insights, which may improve risk stratification and provide therapeutic options for this disease.. ...
Using a selection-based cDNA library screen, we identified the cytokine receptor subunit CRLF2 as a factor in poor-risk B-ALL. The screen, which uses tumor-derived mRNA to assay for transcripts that can substitute for IL3 signaling, is broadly applicable to other tumor types, as many gain-of-function alterations in epithelial and mesenchymal malignancies (e.g., mutant EGFR, KIT, ERBB2, ALK, and EWS) confer IL3 independence in BaF3 cells (29-34). The alterations identified by the screen are functionally relevant and therefore attractive therapeutic targets.. Our data suggests that routine screening of B-ALL for CRLF2 expression, either by IHC or flow cytometry, offers prognostic value. CRLF2 overexpression was associated with high-risk disease in children and a dismal prognosis in adults. Marked enrichment of the adult CRLF2 overexpression signature among pediatric B-ALL suggests that CRLF2 overexpression drives a similar disease in children and adults. Like FLT3 mutations in acute myelogenous ...
The patients in this study showed similar clinical features, as compared with previous reports on iAMP21. Patients with iAMP21 comprised 3.4% of pediatric BCP-ALL patients in this study, which was concordant with 2% in other studies. Other features of iAMP21 such as the presence of a low WBC count and older age at initial diagnosis were also observed. None of the patients were under three years of age. None of the patients showed a WBC count above 50×109/L. In this study, two of 10 cases (20%) showed replacement of a normal chromosome 21 with an abnormal marker chromosome. Four of 10 patients (40%) showed normal karyotype. iAMP21 patients with normal karyotype varied from 0% [1] to 43% [10] in other reports, which could be mainly due to the difference in specimen quality and detection sensitivity of each test.. Some findings in this study have not been clearly described in previous reports. There were significantly more SER in the iAMP21 patient group than in the no iAMP21 patient group. Most ...
The common belief in childhood pB-ALL development is that children with intrinsic genetic susceptibility to pB-ALL development acquire additional chromosomal aberrations, i.e., ETV6-RUNX1-most of them in utero during fetal hematopoiesis-as a primary pathogenetic event followed by a broad range of secondary mutational events resulting in a full-blown leukemia. Common among these secondary events are alterations disrupting the PAX5 gene, which encodes a master transcriptional regulator of B-cell development (13, 14). In this setting, PAX5 seems to retain driver functions in established leukemia because restoring endogenous PAX5 expression triggers disease remission (23).. Recent discoveries of inherited mutations of PAX5 in a new syndrome of susceptibility to pB-ALL have extended the role of PAX5 alterations in the pathogenesis of pB-ALL (5, 6). The presence of the inherited mutations of PAX5 seems to produce a persistent and hidden preleukemic clone that may convert to pB-ALL in only a fraction ...
Relapsed pediatric B-acute lymphoblastic leukemia (B-ALL) remains as the leading cause of cancer death among children. Other than stem cell transplantation and intensified chemotherapy, no other improved treatment strategies have been approved clinically. Gene expression profiling represents a powerful approach to identify potential biomarkers and new therapeutic targets for various diseases including leukemias. However, inadequate sample size in many individual experiments has failed to provide adequate study power to yield translatable findings. With the hope of getting new insights into the biological mechanisms underpinning relapsed ALL and identifying more promising biomarkers or therapeutic targets, we conducted a meta-analysis of gene expression studies involving ALL from 3 separate studies. By using the keywords
Single-agent use of blinatumomab resulted in anti-leukemic activity in patients with tyrosine kinase inhibitor-relapsed or refractory Philadelphia chromosome positive B-precursor acute lymphoblastic leukemia.
Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has achieved an 80% cure rate as a result of a risk-adapted therapy largely based on minimal residual disease (MRD) monitoring. However, relapse is still the most frequent adverse event, occurring mainly in the patients with intermedi …
TY - JOUR. T1 - Six candidate miRNAs associated with early relapse in pediatric b-cell acute lymphoblastic leukemia. AU - Amankwah, Ernest K.. AU - Devidas, Meenakshi. AU - Teachey, David T.. AU - Rabin, Karen R.. AU - Brown, Patrick A.. PY - 2020/6. Y1 - 2020/6. N2 - Background/Aim: Few studies have evaluated the role of miRNAs in pediatric acute lymphoblastic leukemia (ALL) relapse and a consensus of a clinically significant miRNA signature is yet to be identified. In this study, we evaluated miRNAs associated with pediatric B-ALL early relapse in two independent sample sets. Materials and Methods: We performed global miRNA profiling on diagnostic bone marrow specimens from six early relapse (?3 years after diagnosis) and six age- and cytogenetics-matched prolonged remission (?4 years) patients (first set) and an independent set of 14 early relapse and 14 matched prolonged remission specimens (second set). Results: Twelve and 39 top differentially expressed miRNAs were observed in the first ...
TY - JOUR. T1 - B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR. T2 - A clinically aggressive subset of disease. AU - Jaso, Jesse M.. AU - Yin, C. Cameron. AU - Lu, Victoria W.. AU - Zhao, Ming. AU - Abruzzo, Lynne V.. AU - You, M. James. AU - Yang, Yaling. AU - Luthra, Raja. AU - Medeiros, L. Jeffrey. AU - Lu, Gary. PY - 2014/3/1. Y1 - 2014/3/1. N2 - B acute lymphoblastic leukemia (B-ALL) with t(14;19)(q32;p13.1), in which IGH and EPOR are juxtaposed, has been reported rarely. We describe the clinicopathological features of six patients, three men and three women, with a median age of 39 years. Initial and follow-up bone marrow samples were examined from each patient. The clinical, morphologic, and immunophenotypic results were compared with data obtained from conventional cytogenetic analysis and by using home-brew fluorescence in situ hybridization (FISH) probes for IGH at 14q32 and EPOR at 19p13.1. The bone marrow specimens were hypercellular (median 90%; range ...
abnormalities might serve as focus on for precision medications in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). that further marketing and evaluation of JAK inhibitor treatment is essential ahead of its scientific integration in pediatric BCP-ALL. have already been determined [3C16]. Genomic 345627-80-7 translocations of have already been seen in high-risk [6, 9, 10]. Certainly, requirement of the relationship of mutant using a cytokine receptor was proven in cell lines versions by several groupings [6, 8, 9]. Mutations and translocations represent biologically specific entities, but both are potential goals for precision medications. JAK inhibitors had been been shown to be effective against mutant and translocated [3, 5, 345627-80-7 7, 8, 12, 13, 17, 18]. Nevertheless, mouse studies also show conflicting data and non-e continues to be reported to become curative [13, 18C22]. To time, scientific data with JAK inhibitors are scarce. The Childrens Oncology Group performed a ...
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene encodes a cytoplasmic linker or adaptor protein that plays a critical role in B cell development. This protein bridges B cell receptor-associated kinase activation with downstream signaling pathways, thereby affecting various biological functions. The phosphorylation of five tyrosine residues is necessary for this protein to nucleate distinct signaling effectors following B cell receptor activation. Mutations in this gene cause hypoglobulinemia and absent B cells, a disease in which the pro- to pre-B-cell transition is developmentally blocked. Deficiency in this protein has also been shown in some cases of pre-B acute lymphoblastic leukemia. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, May 2012 ...
Bryant, age five, was diagnosed with Pre-B Acute Lymphoblastic Leukemia in April 2014. At the time of his diagnosis he was the typical 3-year-old, who loved to say
Parthenolide (a compound from Feverfew) induces significant programmed cell death in pre-B acute lymphoblastic leukemia (ALL) cell lines.
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
Start-up company Micromet owned the intellectual property rights, and when it was acquired these were transferred to Amgen, which now markets Blincyto in the United States following the drugs approval by the FDA. Prof. Thomas Sommer, interim Scientific Director at MDC, says: The MDCs basic research has borne fruit. The path to drug approval is often a long and difficult one, but the example set by Blinatumomab and other promising MDC projects show that we are on the right track.. Blincyto is used to treat B-cell acute lymphoblastic leukemia (full name: Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia or pre-B-cell ALL). In the U.S., Blincyto was granted breakthrough therapy designation for treating this specific type of leukemia. Patients suffering from the disease usually have a prognosis of only a few months survival time. The drug signifies new hope for these patients. It will be used in situations where conventional treatment will no longer lead to recovery ...
Precursor B cell acute lymphoblastic leukemia (BCP-ALL) constitutes the leading cause of cancer-related death in children. While chromosomal alterations contribute to BCP-ALL pathogenesis, they are insufficient for leukemia development. Epidemiological data and evidence from a mouse model suggest that immune responses to infections may trigger the emergence of leukemia, but the mechanisms remain unclear. Here, we show that T helper (Th) cells from bone marrow of pediatric BCP-ALL patients can be attracted and activated by autologous BCP-ALL cells. Bone-marrow Th cells supportively interacted with BCP-ALL cells, inducing upregulation of important surface molecules and BCP-ALL cell proliferation. These Th cells displayed a Th1-like phenotype and produced high levels of IFN-γ. IFN-γ was responsible for the upregulation of CD38 in BCP-ALL cells, a molecule which we found to be associated with early relapse, and accountable for the production of IP-10, a chemokine involved in BCP-ALL migration and ...
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Monoclonal antibodies, such as blinatumomab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia ...
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Immunotherapy with blinatumomab, may induce changes in bodys immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia ...
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low, said Richard Pazdur, M.D., director of the FDAs Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDAs Center for Drug Evaluation and Research. These patients have few treatments available and todays approval provides a new, targeted treatment option.. B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. The National Cancer Institute estimates that approximately 5,970 people in the United States will be diagnosed with ALL this year and approximately 1,440 will die from the ...
On December 3, 2014, blinatumomab (Blincyto) was granted accelerated approval for use in treating Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).1,2. Supporting Trial. Approval was based on results of a single-arm trial in 185 patients showing achievement of durable complete remission/complete remission with partial hematologic recovery. Blinatumomab was administered by continuous infusion for 4 weeks of a 6-week cycle. In the first cycle, the initial dose was 9 µg/d for week 1, then 28 µg/d for the remaining 3 weeks. The target dose of 28 µg/d was administered in cycle 2 and subsequent cycles starting on day 1 of each cycle.. Among treated patients, the median age was 39 years (range, 18-79 years), 34% had undergone hematopoietic stem cell transplantation prior to receiving blinatumomab, and 17% had received more than two prior salvage therapies.. Complete remission/complete remission with partial hematologic recovery within two ...
THURSDAY, March 29, 2018 (HealthDay News) - The U.S. Food and Drug Administration says it has expanded approval for Blincyto (blinatumomab) to include adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but who still have minimal residual disease (MRD).. MRD describes the presence of cancer cells in the body, but below levels that can be seen in a microscope, the agency said Thursday in a news release. This condition raises a persons chances that the cancer will come back.. Because patients who have MRD are more likely to relapse, having a treatment option that eliminates even very low amounts of residual leukemia cells may help keep the cancer in remission longer, said Dr. Richard Pazdur, director of the agencys Oncology Center of Excellence.. The affected type of leukemia is an aggressive cancer in which the bone marrow makes too many B-cell lymphocytes, an immature white blood cell. Nearly 6,000 people in the United States are projected to be ...
ON OCTOBER 18, the U.S. Food and Drug Administration (FDA) approved axicabtagene ciloleucel (Yescarta), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Axicabtagene ciloleucel, a chimeric antigen receptor (CAR) T-cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma. (On August 30, 2017, the FDA approved the CAR T-cell immunotherapy, tisagenlecleucel [Kymriah], for the treatment of patients up to age 25 years with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.) A Scientific Paradigm [OCTOBER 18 ] MARKS another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases. In just several decades, gene therapy has gone from being a promising concept to a practical solution to deadly and largely untreatable ...
Ribera J, Zamora L, Morgades M, Mallo M, Solanes N, Batlle M, Vives S, Granada I, Juncà J, Malinverni R, Genescà E, Guàrdia R, Mercadal S, Escoda L, Martinez-Lopez J, Tormo M, Esteve J, Pratcorona M, Martinez-Losada C, Solé F, Feliu E, Ribera JM; Spanish PETHEMA Group; Spanish Society of Hematology. (2017). Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms. Gene Chromosome Canc 56, 812-820 ...
Despite the favorable prognosis of childhood acute lymphoblastic leukemia (ALL), a substantial subset of patients relapses. As this occurs not only in the high risk but also in the standard/intermediate groups, the presently used risk stratification is suboptimal. The underlying mechanisms for treatment failure include the presence of genetic changes causing insensitivity to the therapy administered. To identify relapse-associated aberrations, we performed single-nucleotide polymorphism array analyses of 307 uniformly treated, consecutive pediatric ALL cases accrued during 1992-2011. Recurrent aberrations of 14 genes in patients who subsequently relapsed or had induction failure were detected. Of these, deletions/uniparental isodisomies of ADD3, ATP10A, EBF1, IKZF1, PAN3, RAG1, SPRED1 and TBL1XR1 were significantly more common in B-cell precursor ALL patients who relapsed compared with those remaining in complete remission. In univariate analyses, age (,= 10 years), white blood cell counts (,100 ...
This phase III trial is assessing the efficacy, tolerability and quality-of-life effects of induction therapy with cytarabine + vincristine + dexamethasone +
TY - JOUR. T1 - Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL. AU - Chow, Marilynn. AU - Gao, Lina. AU - MacManiman, Jason D.. AU - Bicocca, Vincent T.. AU - Chang, Bill. AU - Alumkal, Joshi. AU - Tyner, Jeffrey. PY - 2018/5/30. Y1 - 2018/5/30. N2 - Expression of the transmembrane pseudokinase ROR1 is required for survival of t(1;19)-pre-B-cell acute lymphoblastic leukemia (t(1;19) pre-B-ALL), chronic lymphocytic leukemia, and many solid tumors. However, targeting ROR1 with small-molecules has been challenging due to the absence of ROR1 kinase activity. To identify genes that regulate ROR1 expression and may, therefore, serve as surrogate drug targets, we employed an siRNA screening approach and determined that the epigenetic regulator and E3 ubiquitin ligase, UHRF1, is required for t(1;19) pre-B-ALL cell viability in a ROR1-dependent manner. Upon UHRF1 silencing, ROR1 protein is reduced without altering ROR1 mRNA, and ectopically expressed UHRF1 ...
The incidence of acute leukemia is approximately 4 cases per 100,000 per year. 30% of these are ALL. ALL is generally seen in children 75% of cases are usually in children under 6 years of age. There are approximately 3200 cases of ALL in the United States per year; 80-85% of these are precursor B-ALL, the others are precursor T-ALL. The overall cure rate in children is 85%, and about 50% of adults have long-term disease-free survival.. ...
In August 2019, the U.S. Food and Drug Administration granted breakthrough therapy designation to an experimental immunotherapy being developed in the Center for Cancer Research (CCR) for the treatment of B-cell acute lymphoblastic leukemia (ALL), a type of blood cancer. The designation will advance CCRs development and testing of an immunotherapy for children and young
Lineage switch is a very rare event in blastic crisis of chronic myelogenous leukemia (CML-BC). To our knowledge, only three cases of lineage switch between lymphoid and myeloid/myelomonocytic lineages have been reported in the literature. Here, we r
Relapsed or refractory B acute lymphoblastic leukemia (B-ALL) in adults has a poor prognosis, with an expected median survival of less than 6 months. An emerging therapy for adult B-ALL is through T cells that target tumor cells with chimeric antigen receptors (CARs). Davila et al. now report the results of a phase 1 clinical trial of CAR T cells in 16 relapsed or refractory adult patients.. The CD19-targeting CAR T cell therapy resulted in an 88% complete response rate, which allowed most of the patients to transition to allogeneic hematopoietic stem cell transplantation-the current standard of care. Moreover, the authors carefully characterized cytokine release syndrome (CRS), which is a series of toxicities associated with CAR T cell therapy. They found that serum C-reactive protein (CRP) associated with the severity of CRS, which should allow for identification of the subset of patients who will likely require therapeutic intervention with corticosteroids or interleukin-6 receptor blockade ...
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. ...
Abstract: Hox genes encode a family of homeodomain-containing transcription factors that are critical for body plan specification and tissue morphogenesis during embryonic development. Hoxa9, in particular, is required for adult hematopoiesis in which it promotes stem cell renewal and expansion. Most importantly, Hoxa9 is commonly dysregulated in various types of acute leukemia, including acute myeloid leukemia (AML), and T- and B-precursor acute lymphoblastic leukemia (B-ALL and T-ALL). Together with its co-factor MEIS1, HOXA9 plays a causal role in driving leukemic transformation. Hoxa9 dysregulation is also linked to various types of solid tumors, and both gain and loss of function have been implicated in tumorigenesis. Despite its central role, the mechanism through which HOXA9 mediates oncogenic transformation remains poorly understood. Previous work in our lab found that in a HOXA9/MEIS1-driven AML cell line, HOXA9 primarily binds to promoter-distal regions of the genome. Its target ...
|span style=font-family:Times,serif;font-size:9pt;>The HB7 monoclonal antibody specifically binds to human CD38. CD38 is a type II transmembrane glycoprotein of 45 kDa with a protein core of 35 kDa. The CD38 antigen is expressed on essentially all pre-B lymphocytes, plasma cells, and thymocytes. It is also present on activated T lymphocytes, natural killer (NK) lymphocytes, myeloblasts, and erythroblasts. The antigen is expressed during the early stages of T- and B-lymphocyte differentiation, is lost during the intermediate stages of maturation, and then reappears during the final stages of maturation. The CD38 antigen is expressed on 90% of CD34+ cells, and is not expressed on pluripotent stem cells. Coexpression of CD38 antigen on CD34+ cells indicates lineage commitment of those cells. CD38 is a counter-receptor of CD31. It is also expressed in T- and B-acute lymphoblastic leukemia (ALL), Burkitts lymphoma, multiple myeloma, acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL).|
Syvanen M, Ducore J. Whole genome comparisons reveals a possible chimeric origin for a major metazoan assemblage. Journal of Biological Systems, (18) 261-75. 2010. Zunino SJ, Storms DH, Ducore JM. Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11). Cancer Lett. 2010 Oct 1;296(1):49-54. Epub 2010 Apr 9.. Zunino SJ, Storms DH, Ducore JM. Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t(4;11). Int J Oncol. 2010 Nov;37(5):1307-13.. Gofman I, Ducore JM. Risk Factors for the Development of Obesity in Children Surviving ALL and NHL. Journal of Pediatric Hematologyl Oncology, 31(2): 101-107. 2008. Zunino SJ, Ducore JM, Storms DH. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells. Cancer Letters, 254(1): 119-27. 2007. Winter S, Holdsworth MT, Devidas M, Raisch OW, ...
Chromosomal translocations involving the immunoglobulin heavy chain (IGH) locus have been described in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). One of these, t (6;14)(p22;q32), involved the Inhibitor of DNA Binding 4 (ID4) gene, resulting in deregulated ID4 expression. Members of the ID family are helix-loop-helix proteins that lack DNA binding domains. They are thought to regulate cellular differentiation and proliferation by binding and sequestering E proteins from their DNA targets. The aim of this thesis was to examine the expression and oncogenic potential of ID4 in B-cells. ID4 expression was detected in a subset of chronic lymphocytic leukaemia (CLL) and BCP-ALL lacking the ID4/IGH chromosomal translocation. ID4 expression defined a subtype of BCP-ALL with a distinctive gene signature. ID4, unlike other members of the ID family is not expressed in normal B-cells. Unexpectedly, ectopic ID4 protein expression in most but not all derived B-cell lines reduced proliferation ...
Immune regulation is crucial for the pathogenesis of B-cell acute lymphoblastic leukemia (B-ALL). It has been reported that Th17 cells as a newly identified subset of CD4+ T cells are involved in the pathogenesis of several hematological disorders. However, the role of Th17 cells in the pathophysiology of B-ALL is still unclear. The frequencies of T cells were determined by flow cytometry in the peripheral blood and bone marrow of 44 newly diagnosed B-ALL patients and 25 age-matched healthy donors. The cell viability and apoptosis were determined by CCK-8 assay and Annexin V staining, respectively. Western blot was applied to identify the level of Akt and Stat3 phosphorylation. We assessed and observed a significantly increased frequency of Th17 cells and a drastically decreased frequency of Th1 cells in peripheral blood mononuclear cells and bone marrow mononuclear cells from newly diagnosed B-ALL patients compared with healthy donors. Furthermore, increased levels of Th17-related cytokines including
Sigma-Aldrich offers abstracts and full-text articles by [N Yuan, L Song, W Lin, Y Cao, F Xu, S Liu, A Zhang, Z Wang, X Li, Y Fang, H Zhang, W Zhao, S Hu, J Wang, S Zhang].
Children with trisomy 21/Straight down syndrome (DS) are in high risk to build up acute megakaryoblastic leukemia (DS-AMKL) as well as the related transient leukemia (DS-TL). whereas in breasts cancer, high appearance Tmem26 degrees of mediate down-regulation of (HER2) and (HER3), thus suppressing tumor development (Scott et al. 2007). The homolog is certainly involved with translocations found in precursor B-cell acute lymphoblastic leukemia (pre-B ALL) and myelodysplastic syndrome (MDS) (Sonoki et al. 2005; Bousquet et al. 2008). However, RS-127445 the role of Hsa21-encoded in leukemogenesis has not been defined. Physique 1. Hsa21-encoded is usually up-regulated in AMKL patient samples. (and four other miRNAs (in hematopoiesis and leukemogenesis. Using a genetic approach, we exhibited that, in both murine and human contexts, overexpression of led to specific hyperproliferation and enhanced self-renewal capacity of megakaryocytic progenitors (MPs) and megakaryocytic/erythroid progenitors ...
DEERFIELD, Ill., January 15, 2015 - Walgreens today announced that, effective immediately, Walgreens Infusion Services will serve as a limited network home infusion provider for BLINCYTO™ (blinatumomab), a therapy for the treatment of patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). BLINCYTO™ can now be obtained through and administered by Walgreens Infusion Services.. Through our nationwide, community-based infusion services, we deliver comprehensive and collaborative patient care for those with complex conditions and were pleased to be able to provide home infusion services to appropriate patients requiring immunotherapy to treat this rare form of ALL, said Paul Mastrapa, president, Walgreens Infusion Services.. Walgreens Infusion Services specially trained infusion nurses and pharmacists treat patients with a wide range of acute, chronic and rare conditions. As the nations largest provider of home and ...
Pfizer Inc. (NYSE:PFE) today announced that a Biologics License Application (BLA) for inotuzumab ozogamicin has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). Inotuzumab ozogamicin is being evaluated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. Inotuzumab ozogamicin received Breakthrough Therapy designation from the FDA in October 2015 for ALL. Priority Review status accelerates FDA review time from 10 months to a goal of six months from the day of acceptance of filing, and is given to drugs that may offer major advances in treatment or may provide a treatment for which no adequate therapy exists. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in August 2017.. ALL that has recurred after, or is refractory to, first-line therapy is a rapidly progressing and deadly disease, said Mace Rothenberg, MD, chief development officer, Oncology, ...
Clinical trial for childhood ALL , Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Leukemogenesis is a multi-step process which involves the disruption of the normal development of a hematopoetic cell. Precursor-B acute lymphoblastic leukemia (Pre-B ALL) is one such example of the process of leukemogenesis that results from deregulated early B cell development in the bone marrow. Typically, checkpoints which are present at every stage of development safeguard an early B cell from leukemic transformation. This thesis focuses on two such critical cell signaling mechanisms that act at the pre-B cell receptor (pre-BCR) checkpoint (Fraction C), and thereby protect the cell from overt leukemogenesis. While one of the mechanisms protects the B cell from acquiring genetic alterations, the other eliminates deleterious B cells by a process known as negative selection. ❧ In the first half of this thesis, we highlight the novel role of IL7R as the guardian of the B cell genome before Fraction D. We show that IL7R carries out this function by preventing pre-mature expression of AID and ...
The connective tissue growth factor gene (CTGF) is aberrantly expressed in 75% of precursor B-cell acute lymphoblastic leukaemias (pre-B ALL) and is associated with poor outcome. We identified consistent hypomethylation of the CTGF locus in primary pre-B ALL specimens regardless of CTGF expression. By contrast, primary T-cell ALL specimens, which do not express CTGF, exhibited distinctive patterns of hypermethylation. Furthermore, we confirmed that global changes in DNA methylation and histone acetylation can both functionally modulate CTGF expression in pre-B ALL cell lines. These data suggest that hypomethylation of the CTGF locus is an essential prerequisite for aberrant CTGF expression in pre-B ALL.. ...
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous ...
An intensive induction regimen, consisting of idarubicin and high dose cytarabine, was assessed in 19 adult patients, median age 44 years, with newly diagnosed precursor-B acute lymphoblastic leukemia (ALL). Patients achieving a complete response (CR) were given an attenuated consolidation course. The primary endpoints were induction death rate and incidence of serious non-hematological toxicity. Grades 3-4 diarrhoea occurred in 47% of patients during induction. Two patients (11%) died during induction therapy, and 2 were withdrawn due to resistant disease or prolonged marrow hypoplasia. Fifteen patients achieved CR (79%), but levels of minimal residual disease (MRD) after induction were comparable with those previously observed using a modified pediatric protocol. Overall survival at 5 years was 36.8% while leukemia-free survival was 44.1%. An intensive AML protocol used in adults with ALL resulted in substantial toxicity and provided similar levels of cytoreduction to conventional ALL ...
Rosai-Dorfman disease (RDD) is a rare form of histiocytosis characterized by histiocyte proliferation within lymph nodes and extranodal tissue. Here we report an unusual presentation of RDD in an Italian toddler. Moreover, we reviewed the pediatric case reports published between 2004 and 2014, focusing in particular on medical therapy. We report the case of a 14-month-old child who developed a progressive swelling of the right parotid, associated with systemic symptoms and abnormal blood tests. During diagnostic work-up, cervical, intraparotid, and unilateral hilar lymphadenopathies were found. Histopathological and immunohistochemistry studies of a cervical lymph node biopsy established the diagnosis of RDD, with positive PCR for Epstein - Barr virus on the biopsy specimen. Oral steroid therapy was started with progressive reduction in size of all lesions, resolution of systemic symptoms, and normalization of blood tests. RDD is generally considered a benign and self-limiting form of histiocytosis,
TY - JOUR. T1 - BLNK suppresses pre B-cell leukemogenesis through inhibition of JAK3. AU - Nakayama, Joji. AU - Yamamoto, Mutsumi. AU - Hayashi, Katsuhiko. AU - Satoh, Hitoshi. AU - Bundo, Kenji. AU - Kubo, Masato. AU - Goitsuka, Ryo. AU - Farrar, Michael A.. AU - Kitamura, Daisuke. PY - 2009/2/12. Y1 - 2009/2/12. N2 - Pre - B-cell leukemia spontaneously develops in BLNK-deficient mice, and pre - B-cell acute lymphoblastic leukemia cells in children often lack BLNK protein expression, demonstrating that BLNK functions as a tumor suppressor. However, the mechanism by which BLNK suppresses pre - B-cell leukemia, as well as the identification of other genetic alterations that collaborate with BLNK deficiency to cause leukemogenesis, are still unknown. Here, we demonstrate that the JAK3/STAT5 signaling pathway is constitutively activated in pre-B leukemia cells derived from BLNK -/- mice, mostly due to autocrine production of IL-7. Inhibition of IL-7R signaling or JAK3/STAT5 activity resulted in the ...
Research from the Pediatric Cancer Genome Project identifies the mechanism of action for two transcription factors underlying a type of B-precursor acute lymphoblastic leukemia.
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patients clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician ...
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patients clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician ...
Results of a phase 3 study presented at ASH 2019 are suggesting blinatumomab was more effective than chemotherapy as a post-reinduction therapy in high and intermediate risk first relapse of b-acute lymphoblastic leukemia.
Jin Yang, Bao-Ling Qiu, Chen-Yan Zhou, Qi Zhou, Jian-Qin Li, Jian Pan, Wei-Ying Gu, Xiao-Fei Qi, Rui-Hua Chen, Yi-Na Niu, CS Chen, Shao-Yan Hu: Expression and clinical value of multidrug resistance-associated proteins (MRP) 1 to 6 in Chinese pediatric patients with B-precursor acute lymphoblastic leukemia. Int J Clin Exp Pathol 2017;10(2):1708-1718. (Abstract IJCEP0044754, Full text PDF ...
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute
Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood, and B-cell is the most common type of ALL. In childhood ALL, the most important prognostic factor is treatment and without effective treatment, ALL is a fatal illness. So far, different treatment protocols are employed for ALL chemotherapy. Each of these treatment protocols has different side effects and prognosis.In the current study, the children oncology group (COG) protocol was compared with the modified protocols, based on the Berlin-Frankfurt-Munster (BFM) protocol, called the Mofid Childrens Hospital protocol (MCHP). The current study was conducted on 108 patients; 51 patients with COG protocol and 57 with MCHP; 61.1% of patients had pre B-cell ALL type and 38.9% had early pre B-cell ALL type.Induction failures in the COG and MCHP groups were 5.9% and 10.5%, respectively (P = 0.390). In the two groups, the most common recurrence sites were bone marrow (BM) and central nervous system (CNS). Moreover, the incidence of
My only son Max Andrei Josh Y. Gutiza is diagnosed with B-Cell Acute Lymphoblastic Leukemia. Hes only 3 years old. He was admitted at Medical Center Manila last September 14, 2017 because of fever and low platelet count. He tested negative for Dengue, twice, but because his platelet count was only 10, with 150 as a normal count, he needed blood transfusion. It was Monday, September 18, 2017 when he had Bone Marrow Aspiration. Bone marrow aspiration is a procedure that involves taking a sample from the soft tissue inside your bones. He was also tested for blood infection which came out negative. September 19, 2017, the result finally came out. As per his bone marrow aspiration result, 70% leading to B-cell Acute Lymphoblastic Leukemia. He still needs to undergo transfusion because his platelet count is still very low. We were hoping that the remaining 30% will change the results. However, it was not the result we were praying for. Our bill with the said hospital was Php 123,000.00. We never ...
A phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia. Trial wi
COG AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy). Patients must be ≥ 365 days and , 10 years of age (B-ALL patients without DS). Patients must be ≥ 365 days and ≤ 31 years of age (B-ALL patients with DS). Patients must be ≥ 365 days and ≤ 31 years of age (B-LLy patients with or without DS) ...
For long, T-cell acute lymphoblastic leukemia (T-ALL) remained in the shadow of precursor B-ALL because it was more seldom, and showed a normal karyotype in more than 50% of cases. The last decennia, intense research has been carried out on different fronts. On one side, development of normal thymocyte and its regulation mechanisms have been studied in multiple mouse models and subsequently validated. On the other side, molecular cytogenetics (fluorescence in situ hybridization) and mutation analysis revealed cytogenetically cryptic aberrations in almost all cases of T-ALL. Also, expression microarray analysis disclosed gene expression signatures that recapitulate specific stages of thymocyte development. Investigations are still very much actual, fed by the discovery of new genetic aberrations. In this review, we present a summary of the current cytogenetic changes associated with T-ALL. The genes deregulated by translocations or mutations appear to encode proteins that are also implicated in ...
Acute NT was reported in 95 of 1,218 (7.8%) eligible patients treated on POG 9005. The incidence by regimen was regimen A, 46 of 543 patients (8.3%); regimen B, 13 of 354 patients (3.7%); and regimen C, 36 of 321 patients (11.2%) (P , .001). The majority of events were seizures and the median number of days to first occurrence of symptomatic NT after ITM or TIT was 10 to 11 days. Computed tomography (CT) or magnetic resonance imaging (MRI) evidence consistent with leukoencephalopathy (LE), with or without the presence of cerebral calcifications, was observed in 75% and 77.1 % of symptomatic patients treated on regimens A and C, respectively, but in only 15.4% of symptomatic patients treated on regimen B (P , .001). Factors associated with an increased incidence of NT included increased cumulative exposure with repeated i.v. MTX (regimens A and C v B), increased MTX-leucovorin (LCV) ratio (regimens A and C v B), and choice and timing of TIT therapy. The use of i.v. MP during intensification did ...
B-cell acute lymphoblastic leukemia (B-ALL) with genetic alterations leading to overexpression of CRLF2 (CRLF2 B-ALL) is associated with poor outcomes. CRLF2 B-ALL is 5 times more common in Hispanic children than others making it a significant biological component of pediatric cancer health disparities. CRLF2 is a component of the receptor complex that is activated by the cytokine, TSLP. Receptor signaling induces Jak/STAT5 and PI3/AKT/mTOR pathway activation and plays a role in the proliferation and differentiation B cell precursors. We found that primary human bone marrow (BM) stroma express TSLP providing an in vivo source of TSLP to stimulate CRLF2 B-ALL cells. Our goal was to develop patient-derived xenograft (PDX) models of CRLF2 B-ALL for studies to understand disease mechanisms and identify therapies to treat CRLF2 B-ALL and reduce the health disparities for Hispanic children with this disease. PDX models are possible because many cytokines produced in the mouse show cross species ...
Our results strongly support the therapeutic potential for our first-in-class CD19-specific 19-28z CAR T cell therapy. Although these results were obtained in a single-center phase 1 study, they support further evaluation of 19-28z CAR T cell therapy for this very poor prognosis population in a multicenter phase 2 clinical trial.. Patients with relapsed B-ALL have few treatment options and a historical remission rate with standard-of-care salvage chemotherapy of about 30% (8-10). Consistent with this overall poor-risk prognosis, nearly all of our patients (88%) were refractory to the physicians choice salvage therapy given before CAR T cell infusion (Table 1). In contrast, patients treated with 19-28z CD19 CAR T cells had a very high overall complete response rate (88%), with 86% of the patients from this CR group further classified (12 of 14 patients) as MRD− (CRm) (Tables 2 and 4). Subjects with MRD or overt morphologic residual leukemia after salvage chemotherapy were enrolled in our ...
Acute lymphoblastic leukemia (ALL) is a heterogeneous form of hematological cancer consisting of various subtypes. We are interested to study the genetic aberration in precursor B-cell ALL with specific t(12;21) translocation in childhood ALL patient
Meeting Abstract: CT102 -- 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) -- APR 05-09, 2014 -- San Diego, CA -- S -- Source: ...
Novel treatment approaches are needed for patients with acute lymphoblastic leukemia (ALL) who respond poorly to current therapies. The genotypic diversity identified recently by next generation sequencing technologies within ALL calls for individualized novel strategies. However, functional correlations of oncogenic lesions with drug response profiles are ill defined for ALL. We have established an imaging-based cell viability analysis platform to generate drug response profiles for primary patient-derived ALL samples co-cultured with mesenchymal stroma cells, expecting to derive functional information directly from individual patient samples. Such response profiles may mirror perturbations in relevant cellular programs that could be exploited therapeutically. Our pipeline integrates high-content screening, newly developed bioinformatics tools and biochemical approaches. We screened a library of 65 compounds for activity in 37 precursor B-ALL and 23 T-ALL samples including refractory cases. ...
Here we describe a protocol for isolating subsets of precursor B-cells from umbilical cord blood. A sufficient quantity and quality of ...
After three patients with B-cell acute lymphoblastic leukemia suffered fatal cerebral edemas during Juno Therapeutics phase II trial of a CAR-T therapy in July, company officials moved quickly to stop the trial and alert the FDA. Regulators responded by issuing a full clinical hold on the trial-halting treatment of enrolled patients and preventing new accrual-pending an investigation by the company.. Clinical holds have the potential to significantly delay or even end an experimental drugs path to market, but Junos experience turned into a best-case scenario. Regulators lifted the hold 3 days later, after Juno officials supplied data indicating that the deaths were due to an overly intensive chemotherapy regimen of fludarabine and cyclophosphamide given prior to the CAR-T therapy. The trial resumed after fludarabine was dropped.. Although single-agent cyclophosphamide had been used to debulk tumors in earlier trials, some evidence suggested that adding a second agent could lead to better ...
This article originally appeared on Time.com.. An advisory panel for the FDA recommended approving the first gene therapy for use in the U.S., and the treatment is meant for children with B-cell acute lymphoblastic leukemia, the most common blood cancer in children. The FDA doesnt have to follow the advice of the advisory committee, but it often does.. The new therapy, called chimeric antigen receptor T cell (CAR-T) therapy, provides new hope that the disease wont just be treated, but cured. Its based on using the immune system to fight against cancer-currently the most promising way to fight tumors. Cancer cells arise from normal cells, so the immune system doesnt always recognize that anything is wrong. A pioneering group of drugs already approved by the Food and Drug Administration (FDA), called checkpoint inhibitors, remove the brakes on the immune system and allow it to attack tumor cells that it normally wouldnt.. The newly approved therapy CAR-T therapy works to co-opt the immune ...
As CLN Stat has reported previously, immunotherapy continues to gain ground in the fight against cancer, particularly melanoma. Now research finds success harnessing the bodys immune system against Merkel cell carcinoma, head and neck cancer, and B-cell acute lymphoblastic leukemia.
This gene encodes a member of the E protein (class I) family of helix-loop-helix transcription factors. E proteins activate transcription by binding to regulatory E-box sequences on target genes as heterodimers or homodimers, and are inhibited by heterodimerization with inhibitor of DNA-binding (class IV) helix-loop-helix proteins. E proteins play a critical role in lymphopoiesis, and the encoded protein is required for B and T lymphocyte development. Deletion of this gene or diminished activity of the encoded protein may play a role in lymphoid malignancies. This gene is also involved in several chromosomal translocations that are associated with lymphoid malignancies including pre-B-cell acute lymphoblastic leukemia (t(1;19), with PBX1), childhood leukemia (t(19;19), with TFPT) and acute leukemia (t(12;19), with ZNF384). Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene, and a pseudogene of this gene is located on the short arm of chromosome ...
Top 10 cancers for 11760158_at (Homo sapiens, Affymetrix Probeset): Burkitt lymphoma, NOS, leukemia/lymphoma(E2A PBX1 / TCF3 PBX1), precursor-B-ALL, PDX/CDX, colon, adenoma, NOS, prostate, adenocarcinoma, NOS, metastatic, chronic myelogenous leukemia (BCR/ABL-positive), pancreatic duct, intraductal papillary-mucinous carcinoma, invasive, pro-B-ALL, leukemia/lymphoma (MLL rearranged), malignant lymphoma, follicular, NOS
MedHelps Acute Lymphoblastic Leukemia Help Forum. This forum is for help, questions and support regarding Acute Lymphoblastic Leukemia
A critical event in the adaptation to extrauterine life is relaxation of the pulmonary vasculature at birth, allowing for a rapid increase in pulmonary blood flow that is essential for efficient gas exchange. Failure of this transition leads to pulmonary hypertension (PH), a major cause of newborn mortality associated with preterm birth, infection, hypoxia, and malformations including congenital diaphragmatic hernia (CDH). While individual vasoconstrictor and dilator genes have been identified, the coordination of their expression is not well understood. Here, we found that lung mesenchyme-specific deletion of CDH-implicated genes encoding pre-B cell leukemia transcription factors (Pbx) led to lethal PH in mice shortly after birth. Loss of Pbx genes resulted in the misexpression of both vasoconstrictors and vasodilators in multiple pathways that converge to increase phosphorylation of myosin in vascular smooth muscle (VSM) cells, causing persistent constriction. While targeting endothelin and ...
A critical event in the adaptation to extrauterine life is relaxation of the pulmonary vasculature at birth, allowing for a rapid increase in pulmonary blood flow that is essential for efficient gas exchange. Failure of this transition leads to pulmonary hypertension (PH), a major cause of newborn mortality associated with preterm birth, infection, hypoxia, and malformations including congenital diaphragmatic hernia (CDH). While individual vasoconstrictor and dilator genes have been identified, the coordination of their expression is not well understood. Here, we found that lung mesenchyme-specific deletion of CDH-implicated genes encoding pre-B cell leukemia transcription factors (Pbx) led to lethal PH in mice shortly after birth. Loss of Pbx genes resulted in the misexpression of both vasoconstrictors and vasodilators in multiple pathways that converge to increase phosphorylation of myosin in vascular smooth muscle (VSM) cells, causing persistent constriction. While targeting endothelin and ...
The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide. Although gene-environment interactions have been implicated in the etiology of several disorders, the impact of paternal and/or maternal metabolic syndrome on the clinical phenotypes of offspring and the underlying genetic and epigenetic contributors of NAFLD have not been fully explored. To this end, we used the liver-specific insulin receptor knockout (LIRKO) mouse, a unique nondietary model manifesting 3 hallmarks that confer high risk for the development of NAFLD: hyperglycemia, insulin resistance, and dyslipidemia. We report that parental metabolic syndrome epigenetically reprograms members of the TGF-β family, including neuronal regeneration-related protein (NREP) and growth differentiation factor 15 (GDF15). NREP and GDF15 modulate the expression of several genes involved in the regulation of hepatic lipid metabolism. In particular, NREP downregulation increases the protein abundance of ...
A critical event in the adaptation to extrauterine life is relaxation of the pulmonary vasculature at birth, allowing for a rapid increase in pulmonary blood flow that is essential for efficient gas exchange. Failure of this transition leads to pulmonary hypertension (PH), a major cause of newborn mortality associated with preterm birth, infection, hypoxia, and malformations including congenital diaphragmatic hernia (CDH). While individual vasoconstrictor and dilator genes have been identified, the coordination of their expression is not well understood. Here, we found that lung mesenchyme-specific deletion of CDH-implicated genes encoding pre-B cell leukemia transcription factors (Pbx) led to lethal PH in mice shortly after birth. Loss of Pbx genes resulted in the misexpression of both vasoconstrictors and vasodilators in multiple pathways that converge to increase phosphorylation of myosin in vascular smooth muscle (VSM) cells, causing persistent constriction. While targeting endothelin and ...
A critical event in the adaptation to extrauterine life is relaxation of the pulmonary vasculature at birth, allowing for a rapid increase in pulmonary blood flow that is essential for efficient gas exchange. Failure of this transition leads to pulmonary hypertension (PH), a major cause of newborn mortality associated with preterm birth, infection, hypoxia, and malformations including congenital diaphragmatic hernia (CDH). While individual vasoconstrictor and dilator genes have been identified, the coordination of their expression is not well understood. Here, we found that lung mesenchyme-specific deletion of CDH-implicated genes encoding pre-B cell leukemia transcription factors (Pbx) led to lethal PH in mice shortly after birth. Loss of Pbx genes resulted in the misexpression of both vasoconstrictors and vasodilators in multiple pathways that converge to increase phosphorylation of myosin in vascular smooth muscle (VSM) cells, causing persistent constriction. While targeting endothelin and ...
A critical event in the adaptation to extrauterine life is relaxation of the pulmonary vasculature at birth, allowing for a rapid increase in pulmonary blood flow that is essential for efficient gas exchange. Failure of this transition leads to pulmonary hypertension (PH), a major cause of newborn mortality associated with preterm birth, infection, hypoxia, and malformations including congenital diaphragmatic hernia (CDH). While individual vasoconstrictor and dilator genes have been identified, the coordination of their expression is not well understood. Here, we found that lung mesenchyme-specific deletion of CDH-implicated genes encoding pre-B cell leukemia transcription factors (Pbx) led to lethal PH in mice shortly after birth. Loss of Pbx genes resulted in the misexpression of both vasoconstrictors and vasodilators in multiple pathways that converge to increase phosphorylation of myosin in vascular smooth muscle (VSM) cells, causing persistent constriction. While targeting endothelin and ...
This gene encodes a homeobox protein that belongs to the three-amino-acid loop extension/Pre-B cell leukemia transcription factor (TALE/PBX) family of proteins. The encoded protein is involved in several biological processes during embryogenesis including steroidogenesis, sexual development and the maintenance of hematopoietic stem cells. This protein functions in the development of several organ systems and plays a role in skeletal patterning and programming. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2014 ...
An elementary school aged boy with a history of pre-B cell acute lymphocytic leukemia with a failed bone marrow transplant was transferred to a regional childrens hospital for leukodepletion and participation in an experimental clinical trial. At that time, his CBC was significant for 10% polymorphonuclear cells and 50% blasts. He was subsequently transferred to…
During the annual meeting of the American Association for Cancer Research (AACR), the CT078 test results showed that the majority of adult patients with recurrent B cell acute lymphoblastic leukemia…
In 75 pediatric and young adult B-ALL patients who received a tisagenlecleucel infusion in the phase 2 single-cohort ELIANA study (ClinicalTrials.gov Identifier: NCT02435849), the overall 3-month remission rate (the primary end point) was 81%. At 6 months, event-free and overall survival rates were 73% (95% CI, 60%-82%) and 90% (95% CI, 81%-95%), respectively. At 12 months, these rates were 50% (95% CI, 35%-64%) and 76% (95% CI, 63%-86%), respectively. Transient grade 3 or 4 adverse events occurred in 73% of participants, cytokine release syndrome occurred in 77% of patients, and neurologic events occurred in 40% of patients.2 In the phase 1/2 ZUMA-1 study (ClinicalTrials.gov Identifier: NCT02348216), axicabtagene ciloleucel was successfully administered to 101 patients with DLBCL. The primary end point, complete or partial response, was achieved by 83% of patients. Median duration of response and progression-free survival were 11.1 months (95% CI, 4.2-not estimable) and 5.9 months (95% CI, ...
Background. Infections cause significant morbidity in children with acute lymphoblastic leukemia ALL. The incidence of viral infections commonly occurring in children with ALL receiving chemotherapy was compared with viral infections in control children and the spread of infections in families was traced. Methods. Fifteen families of children...
Acute lymphoblastic leukemia information including symptoms, diagnosis, misdiagnosis, treatment, causes, patient stories, videos, forums, prevention, and prognosis.
Here is some information from The Ohio State University Comprehensive Cancer Center - (OSUCCC - James) I wanted to share with you.
Radiation therapy of brain in Acute lymphoblastic leukemia (ALL) with brain damage (costs for program #273491) ✔ University Hospital Jena ✔ Department of Hematology, Oncology and Pallative Medicine ✔ BookingHealth.com
"Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias". Am. J. Clin. Pathol. ... "Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias". Am. J. Clin. Pathol. ... the acute leukemia could be acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). According to the original EGIL ... Persistent fever, infection prolonged healing: Most of the white blood cells are leukemia cells, no normal function, leading to ...
... a wide range of acquired mutations in hematological precursor cells that lead to various types of leukemia and/or lymphoma. It ... chronic myelomonocytic leukemia, acute myelocytic leukemia, B cell acute lymphoblastic leukemia, mixed phenotype acute leukemia ... Sanchez-Martin M, Ferrando A (March 2017). "The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia". Blood. 129 (9 ... of adult T cell Acute lymphoblastic leukemia cases. These mutations involve insertions or deletions in the gene that lead to ...
... acute lymphoblastic leukemia (ALL), hairy cell leukemia, follicular lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, and ... Malignant transformation of B cells and their precursors can cause a host of cancers, including chronic lymphocytic leukemia ( ... B-2 cell - FO B cells and MZ B cells. Follicular (FO) B Cell (also known as a B-2 cell) - Most common type of B cell and, when ... T cells and natural killer cells, express B cell receptors (BCRs) on their cell membrane. BCRs allow the B cell to bind to a ...
... is indicated for the treatment of those under 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is ... large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise ... is a medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight ... The T cells are engineered to target a protein called CD19 that is common on B cells. A chimeric T cell receptor ("CAR-T") is ...
Acute erythroid leukemia Acute lymphoblastic leukemia T-cell acute lymphoblastic leukemia Adult T-cell leukemia/lymphoma ( ... Precursor) T-lymphoblastic leukemia/lymphoma Blast crisis of chronic myelogenous leukemia Wolach, O; Stone, R. M. (2015). "How ... Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original diagnosis of leukemia. In ... Forms of acute leukemia include: Acute myeloid leukemia ... of the malignant cells that grow uncontrolled, but some are ...
... precursor B-cell lymphoblastic leukemia, plasmablastic lymphoma, the high grade subtype of B-cell lymphoma, Hodgkin lymphoma of ... the high grade subtype of B-cell lymphoma, Hodgkin lymphoma of the B-cell type, chronic lymphocytic leukemia/small cell ... or in rare cases exhibit the histology resembling precursor B-cell lymphoblastic leukemia, plasmablastic lymphoma, ... FL may be confused with marginal zone B-cell lymphoma, mantle cell lymphoma, and the small lymphocytic lymphoma variant of ...
Precursor B lymphoblastic leukemia 9940/3 - Hairy cell leukemia T-cell leukemia B-cell lymphoma. ... B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma 9826/3 - Acute lymphoblastic leukemia, mature B-cell type 9833/3 ... A B-cell leukemia is any of several types of lymphoid leukemia which affect B cells. Types include (with ICD-O code): 9823/3 - ...
... of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia ... DNA sequencing of miR-17-92 cluster at chromosome 13q31-q32 in mantel cell lymphoma cell lines]". Zhongguo Shi Yan Xue Ye Xue ... amplification in human mantle cell lymphoma". Leuk Lymphoma. 48 (2): 410-2. doi:10.1080/10428190601059738. PMID 17325905. ... amplification in human mantle cell lymphoma". Leuk Lymphoma. 48 (2): 410-2. doi:10.1080/10428190601059738. PMID 17325905. ...
It is the most common type of acute lymphoblastic leukemia (ALL). It is sometimes additionally classified as a lymphoma, as ... Precursor B-cell lymphoblastic leukemia is a form of lymphoid leukemia in which too many B-cell lymphoblasts (immature white ... Precursor B-lymphoblastic leukemia entry in the public domain NCI Dictionary of Cancer Terms v t e v t e. ... as capable to change phenotype of B cells toward precursor cells. {{,t(12;21)-ETV/ CBFα has a better prognosis as compared to ...
... is used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It is administered ... In May 2013, a phase III trial in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not ... is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia ( ... and the FDA for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia ...
... the lymphoproliferative disorders acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma.[ ... Chronic eosinophilic leukemia (not otherwise specified) MPN, unclassifiable (MPN-U) MPNs arise when precursor cells (blast ... Chronic neutrophilic leukemia Chronic neutrophilic leukemia (CNL) is characterized by a mutation in the CSF3R gene and an ... Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or ...
Hepatocellular carcinoma Chronic lymphocytic leukemia Acute lymphoblastic leukemia Acute myeloid leukemia gastric MALT lymphoma ... "Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and ... More specifically, miR-223 expression suppresses the differentiation of osteoclast precursors into osteoclast thus making it a ... acute lymphoblastic leukemia, acute myeloid leukemia, gastric MALT lymphoma, and recurrent ovarian cancer. Integrative analysis ...
"BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia". "U. ... "FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma". FDA. ... S. FDA Approves Inotuzumab Ozogamicin for Treatment of Patients with R/R B-cell precursor Acute Lymphoblastic Leukemia". ADC ... monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia ...
"Significance of myeloid antigen expression in precursor T lymphoblastic lymphoma. ". Chin J Cancer. 2010. PMID 20193116. ... "Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the ... "Identification of MNDA as a new marker for nodal marginal zone lymphoma.". Leukemia. 2009. PMID 19474799. ... cnewyllyn cell. • extracellular region. • nucleoplasm. • nucleolus. • azurophil granule lumen. • ficolin-1-rich granule lumen. ...
... precursor t-cell acute lymphoblastic leukemia, beichiogrwydd ectopig, polymyositis, diffuse large b-cell lymphoma, t-cell ... central nervous system lymphoma, precursor b-cell acute lymphoblastic leukemia, pemffigaidd pothellog ... precursor t-lymphoblastic lymphoma/leukemia, granulomatosis wegener, liwcemia myeloid aciwt, ... b-cell lymphoma, osteoarthritis susceptibility 1, gwynegon, temporal arteritis, systemic-onset juvenile idiopathic arthritis, ...
B-cell lymphoma, T-cell lymphomas, T cell leukemias, and Langerhans cell histiocytosis. Other hematological diseases are ... Hematopoietic stem cells give rise to: 1) myeloid precursor cells that differentiate into red blood cells, mast cells, blood ... acute myelogenous leukemia, acute lymphoblastic leukemia, or T lymphoblastic lymphoma. These patients usually respond well to ... Such mutations occur in hematological stem cells and/or their daughter myeloid precursor and lymphoid precursor cells; commonly ...
However, tumor cells in some cases of T-lymphoblastic leukemia/lymphoma and AML has shown to potentially react positively with ... expressed by B-cell and plasma cell precursors is a candidate that induces apoptosis as well as inhibition of B-cell receptor ( ... "Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma". Nature. 463 (7277): 88-92. Bibcode:2010Natur.463 ... CD79 serves to be a pan-B cell marker for the detection of B-cell neoplasms. ...
T-cell acute lymphoblastic leukemia * B-cell lymphomas * Cell lines * Cerebellum * Purkinje cells * HeLa cells Finally they ... MiR-19 is sufficient to induce T-cell lymphoblastic leukemia activating Notch1 and accelerate the disease. Its targets are: * ... which provides new clues for sustained activation of NF-kB in T-cell acute lymphoblastic leukemia. ... demonstrated that the expression of endogenous miR-17-92 is required to suppress apoptosis in Myc-driven B-cell lymphomas. More ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Anaplastic large-cell lymphoma is an example of a large-cell lymphoma that involves T cells. Of the large-cell T-cell lymphomas ... B cell[edit]. Diffuse large B-cell lymphoma is the most common of the large-cell lymphomas. MeSH now classifies the phrase " ... which are often diffuse large-B-cell lymphomas. Activated B-Cell Diffuse Large B-Cell Lymphoma, or ABC-DLBCL, is believed to be ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Anaplastic large-cell lymphoma (ALCL) is a form of cancer. It is a type of non-Hodgkin lymphoma involving aberrant T cells or ... The cells are also typically positive for a subset of markers of T-cell lineage. However, as with other T-cell lymphomas, they ... It has been suggested that ALK-negative anaplastic large-cell lymphomas derive from other T-cell lymphomas that are morphologic ...
Lymphomas or leukemias of thymocyte origin are classified as Precursor T acute lymphoblastic leukemia/lymphoma (T-ALL). People ... These syndromes are caused by defective hematopoietic progenitor cells which are the precursors of both B- and T cells. This ... Cells in the thymus can be divided into thymic stromal cells and cells of hematopoietic origin (derived from bone marrow ... Stromal cells include epithelial cells of the thymic cortex and medulla, and dendritic cells. The thymus provides an inductive ...
... large-cell lymphomas, chronic lymphocytic leukemia and acute lymphoblastic leukemia. Toxicity against CD19 results in B cell ... though the expression of these molecules on normal precursors can lead to prolonged myeloablation. BCMA is a tumor necrosis ... Antigen CD19 appears only on B cells, which go awry in lymphoma and leukemia. Loss of B cells can be countered with ... CD4+ T cells can also promote tumor rejection. CD4+ T cells enhance CD8+ T cell function and can directly destroy tumor cells. ...
... malignancy Acute lymphoblastic leukemia Chronic myelogenous leukemia Eosinophilic leukemia Clonal eosinophilia Hodgkin lymphoma ... Maintenance of these levels results from a balance between production of eosinophils by bone marrow eosinophil precursor cells ... In primary cutaneous T cell lymphoma, blood and dermal eosinophilia are often seen. Lymphoma cells have also been shown to ... chronic myelomonocytic leukemia, and certain cases of T-lymphoblastic leukemia/lymphoma-associated or myelodysplastic- ...
"Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells". ... "Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active ... positive childhood T-cell acute lymphoblastic leukemia". European Journal of Haematology. 77 (1): 27-34. doi:10.1111/j.0902- ... "Entrez Gene: [email protected] T cell receptor delta locus". Chien YH, Iwashima M, Kaplan KB, Elliott JF, Davis MM (1987). "A new T-cell ...
... cell linages present with signs and symptoms respectively of acute myeloid leukemia or lymphoma T-lymphoblastic leukemia/ ... occurs in lymphoid precursor cells to promote the proliferation and differentiation of precursor cells along the lymphoid ... while occurring in myeloid precursor cells, promotes proliferation and differentiation of precursor cells along the neutrophil ... the success of Gleevec in treating the myeloproliferative neoplasm/myeloblastic leukemia or T-lymphoblastic leukemia/lymphoma ...
Downregulation of miR16 (as well as miR15) was observed in diffuse large B-cell lymphoma. miR16 has been shown to bind to a ... "Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant ... Caligaris-Cappio F, Hamblin TJ (1999). "B-cell chronic lymphocytic leukemia: a bird of a different feather". J Clin Oncol. 17 ( ... "Accumulation of miR-155 and BIC RNA in human B-cell lymphoma". Proc Natl Acad Sci U S A. 102 (10): 3627-3632. doi:10.1073/pnas. ...
... which is approved by the US FDA for treatment of relapsed/refractory acute lymphoblastic leukemia. He has invented various ... "Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-κB transcription factor". Cell. 53 (2): 211 ... Perkel, Jeffrey (2008-08-14). "New Lymphoma Drug Shows Promise". ISSN 0190-8286. Retrieved 2017-10-04. "TCR2 Therapeutics ... University of Konstanz Max-Planck Institute of Molecular Cell Biology and Genetics Max-Planck Institute for Neurobiology EMBL ...
T cell lymphoma Anaplastic large cell lymphoma Precursor lymphoid neoplasms B-lymphoblastic leukemia/lymphoma not otherwise ... T-cell large granular lymphocyte leukemia Aggressive NK cell leukemia Adult T-cell leukemia/lymphoma Extranodal NK/T-cell ... large B-cell lymphoma ALK+ large B-cell lymphoma Plasmablastic lymphoma Primary effusion lymphoma Large B-cell lymphoma arising ... lymphoma, nasal type Enteropathy-associated T-cell lymphoma Hepatosplenic T-cell lymphoma Blastic NK cell lymphoma Mycosis ...
... tissue lymphoma Mycosis fungoides Nodal marginal zone B cell lymphoma Non-Hodgkin lymphoma Precursor B lymphoblastic leukemia ... cell lymphoma Marginal zone B-cell lymphoma Mast cell leukemia Mediastinal large B cell lymphoma Multiple myeloma/plasma cell ... leukemia Cutaneous T-cell lymphoma Diffuse large B-cell lymphoma Follicular lymphoma Hairy cell leukemia Hepatosplenic T-cell ... myeloid dendritic cell leukemia AIDS-related lymphoma Anaplastic large cell lymphoma Angioimmunoblastic T-cell lymphoma B-cell ...
... some B-cell chronic lymphocytic leukemias, acute lymphoblastic leukemias, and most acute nonlymphocytic leukemias. CD15 is ... The presence of these cells is diagnostic of Hodgkin's lymphoma. Reed-Sternberg cells display a characteristic pattern of ... and ST3GAL6 participate in the synthesis of the Sialyl-Lewis X precursor.(Fig.1) Sialyl-Lewisx is important in leukocyte ... It is known to play a vital role in cell-to-cell recognition processes. It is also the means by which an egg attracts sperm; ...
... restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell ... The Lymphomas (PDF). The Leukemia & Lymphoma Society: 2. May 2006 [2008-04-07]. (原始内容 (PDF)存档于2008-07-06).. 已忽略未知参数. ,url- ... Recognition of Vitamin B Precursors and Byproducts by Mucosal Associated Invariant T Cells. The Journal of Biological Chemistry ... T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer ...
... acute lymphoblastic leukemia, Cri-du-chat, Velocardiofacial syndrome, and Down syndrome. FISH on sperm cells is indicated for ... such as translocations and inversions which are hallmark aberrations seen in many types of leukemia and lymphoma. ... "Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity". RNA. 17 (6): ... A metaphase cell positive for the bcr/abl rearrangement (associated with chronic myelogenous leukemia) using FISH. The ...
... for B-cell acute lymphoblastic leukemia [109] Proteasome inhibitors can kill some types of cultured leukemia cells that are ... "Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in ... Schenkein D (June 2002). "Proteasome inhibitors in the treatment of B-cell malignancies". Clinical Lymphoma. 3 (1): 49-55. doi: ... "Cell. 137 (1): 133-45. doi:10.1016/j.cell.2009.01.041. PMC 2668214. PMID 19345192.. ...
In particularly large tumors and cancers with high white cell counts, such as lymphomas, teratomas, and some leukemias, some ... Two girls with acute lymphoblastic leukemia receiving chemotherapy. The girl at left has a central venous catheter inserted in ... DNA precursors/. antimetabolites. (S phase). Folic acid. *Dihydrofolate reductase inhibitor (Aminopterin. *Methotrexate# ... The most common medications affect mainly the fast-dividing cells of the body, such as blood cells and the cells lining the ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Hodgkin's lymphoma. Follicular dendritic cell sarcoma. Extranodal NK/T-cell lymphoma, nasal type. MCPyV Merkel-cell carcinoma. ... A primary central nervous system lymphoma (PCNSL), also known as microglioma and primary brain lymphoma,[1] is a primary ... of all cases of lymphomas in HIV infections (other types are Burkitt's lymphomas and immunoblastic lymphomas). Primary CNS ...
Lymphoma and leukemia: These two classes arise from hematopoietic (blood-forming) cells that leave the marrow and tend to ... acute lymphoblastic leukemia and brain tumors are most common, except in Africa where non-Hodgkin lymphoma occurs more often.[ ... while a malignancy arising from primitive liver precursor cells is called a hepatoblastoma and a cancer arising from fat cells ... and human T-cell leukemia virus-1 (T-cell leukemias). Bacterial infection may also increase the risk of cancer, as seen in ...
Anaplastic large-cell lymphoma t(2 ALK;5 NPM1). *Acute lymphoblastic leukemia ... Its natural precursor, β-carotene, is considered safe, whereas the consumption of animal liver can lead to malformation, as the ... Male germ cells mutate at a much faster rate than female germ cells, and as the father ages, the DNA of the germ cells mutates ... This is because, as humans age, male germ cells acquire mutations at a much faster rate than female germ cells.[59][32][29] ...
Histopathology of the Thymus of Patients With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in Complete Clinical ... The role of CCL21 in recruitment of T-precursor cells to fetal thymi. Lühikokkuvõte, Blood. 1. jaanuar 2005 ;105(1):31-9. 2005 ... Autoreactive thymic B cells are efficient antigen-presenting cells of cognate self-antigens for T cell negative selection., 110 ... Cell-Autonomous Defects in Thymic Epithelial Cells Disrupt Endothelial-Perivascular Cell Interactions in the Mouse Thymus, 4. ...
"The Lymphomas" (PDF). The Leukemia & Lymphoma Society. May 2006. p. 2. Retrieved 2008-04-07.. ... These immune cells originate as precursor cells, derived from bone marrow,[1] and develop into several distinct types of T ... restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell ... Cytotoxic T cells (TC cells, CTLs, T-killer cells, killer T cells) destroy virus-infected cells and tumor cells, and are also ...
... pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia" ... Anaplastic large-cell lymphoma t(2 ALK;5 NPM1). *Acute lymphoblastic leukemia ... is a specific genetic abnormality in chromosome 22 of leukemia cancer cells (particularly chronic myeloid leukemia (CML) cells ... Nowell was a pathologist at the University of Pennsylvania, studying leukemia cells under the microscope when he noticed cells ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Subtypes include precursor B acute lymphoblastic leukemia, precursor T acute lymphoblastic leukemia, Burkitt's leukemia, and ... Four major kinds of leukemia Cell type. Acute. Chronic Lymphocytic leukemia. (or "lymphoblastic"). Acute lymphoblastic leukemia ... Hairy cell[edit]. Further information: Hairy cell leukemia § Treatment. Decision to treat. Patients with hairy cell leukemia ...
... acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma). ... The increased numbers of blood cells may not cause any symptoms, but a number of medical problems or symptoms may occur. The ... All MPNs arise from precursors of the myeloid lineages in the bone marrow. The lymphoid lineage may produce similar diseases, ... Chronic myeloid leukemiaEdit. Chronic myeloid leukemia (CML) with the defining translocation t(9;22);Philadelphia chromosome ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Hepatitis C virus: associated with splenic marginal zone lymphoma, lymphoplasmacytic lymphoma and diffuse large B-cell lymphoma ... Hodgkin's lymphoma, follicular dendritic cell sarcoma, extranodal NK-T-cell lymphoma[9] ... Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphoma except Hodgkin's lymphomas.[1] ...
Anaplastic large-cell lymphoma t(2 ALK;5 NPM1). *Acute lymphoblastic leukemia ... plasma cell leukemia.[23][41][42] Thus, a fundamental genetic instability in plasma cells or their precursors leads to the ... Stem cell transplant[edit]. Stem cell transplant can be used to treat multiple myeloma.[3] Stem cell transplants come with a ... The normal cell line most closely associated with MM cells is generally taken to be either an activated memory B cell or the ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Hodgkin's lymphoma. Follicular dendritic cell sarcoma. Extranodal NK/T-cell lymphoma, nasal type. MCPyV Merkel-cell carcinoma. ... Since Burkitt lymphoma and other B-cell lymphomas are a clonal proliferative process, all tumor cells from one patient are ... The tumor cells have a similar appearance to the cancer cells of classical endemic Burkitt lymphoma. Sporadic lymphomas are ...
... restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell ... The Lymphomas (PDF). The Leukemia & Lymphoma Society: 2. May 2006 [2008-04-07]. (原始内容存档 (PDF)于2008-07-06).. ,url-status=. 和. , ... Recognition of Vitamin B Precursors and Byproducts by Mucosal Associated Invariant T Cells. The Journal of Biological Chemistry ... 辅助性CD4+/TFH(英语:Follicular B helper T cells)/Th3(英语:T helper 3 cell)/Th17(英语:T helper 17 cell)/调节
"The Lymphomas" (PDF). The Leukemia & Lymphoma Society. May 2006. p. 2. Retrieved 2008-04-07.. ... Common lymphoid precursor cells that migrate to the thymus become known as T-cell precursors (or thymocytes) and do not express ... restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell ... Cytotoxic T cells (TC cells, CTLs, T-killer cells, killer T cells) destroy virus-infected cells and tumor cells, and are also ...
Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. ... acute myeloid leukemia lub acute myelogenous leukemia, AML lub acute non-lymphoblastic leukemia, ANLL) - grupa chorób ... Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. „Leuk Lymphoma". 49 (5), s. 852-63, May 2008. DOI ... Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal ...
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma). *prolymphocyte (Prolymphocytic). *CD30+ (Anaplastic large-cell ... Hodgkin's lymphoma (HL) is a type of lymphoma in which cancer originates from a specific type of white blood cells called ... The cell histology in Hodgkin's lymphoma is not as important as it is in non-Hodgkin's lymphoma: the treatment and prognosis in ... Micrograph showing a "popcorn cell", the Reed-Sternberg cell variant seen in nodular lymphocyte predominant Hodgkin lymphoma. H ...
... is a leukemia of megakaryoblasts, the precursors cells to megakaryocytes which form blood platelets.[46] Acute lymphoblastic ... Anaplastic large-cell lymphoma t(2 ALK;5 NPM1). *Acute lymphoblastic leukemia ... Leukemia is 10 to 15 times more common in children with Down syndrome.[20] In particular, acute lymphoblastic leukemia is 20 ... including acute lymphoblastic leukemia (ALL) and acute megakaryoblastic leukemia (AMKL) is increased while the risk of other ...
... each of which develops from cells originating in mesenchymal cells outside the bone marrow. Lymphoma and leukemia: These two ... In children, acute lymphoblastic leukemia and brain tumors are most common, except in Africa, where non-Hodgkin lymphoma occurs ... while a malignancy arising from primitive liver precursor cells is called a hepatoblastoma and a cancer arising from fat cells ... and human T-cell leukemia virus-1 (T-cell leukemias). Bacterial infection may also increase the risk of cancer, as seen in ...
Ribatti, Domenico (May 2012). "Sidney Farber and the treatment of childhood acute lymphoblastic leukemia with a ... halting cell division in metaphase. With their chromosomes unable to separate, the cells ultimately die. Methotrexate, or ... It operates by inhibiting the production of folic acid, a precursor to cellular DNA that is necessary for DNA synthesis. By ... used today in the treatment of Hodgkin lymphoma. It was one of the earliest combination chemotherapy regimens, originally ...
Lymphoma. Leukemia. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Leukemia, Lymphoid. Neoplasms by Histologic Type. Neoplasms ... Must have relapsed or refractory precursor B-cell acute lymphoblastic leukemia or acute lymphoblastic lymphoma. ... Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma. The safety and ... A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma. ...
Precursor Cell Lymphoblastic Leukemia-Lymphoma , Houston (62 studies) * methodist hospital , Precursor Cell Lymphoblastic ... methodist hospital , Recruiting, Not yet recruiting, Available Studies , Precursor Cell Lymphoblastic Leukemia-Lymphoma (12 ... methodist hospital , Recruiting, Not yet recruiting, Available Studies , Precursor Cell Lymphoblastic Leukemia-Lymphoma , ... methodist hospital , Recruiting, Not yet recruiting, Available Studies , Precursor Cell Lymphoblastic Leukemia-Lymphoma , ...
Precursor lymphoid neoplasms are categorized as B lymphoblastic leukemia/lymphoma and T lymphoblastic leukemia/lymphoma. The B ... Precursor B-Cell Acute Lymphoblastic Leukemia/Lymphoma with L3 Morphology, Philadelphia Chromosome, MYC Gene Translocation, and ... or T-cell lineage. The immature cells in B-acute lymphoblastic leukemia/lymphoma can be small or medium sized with scant or ... Burkitt leukemia/lymphoma is now considered a mature B-cell neoplasm. It was formerly classified as precursor B ALL with L3 ...
... kills a wide range of both myeloid and lymphoid cell lines with precursor T-cell lymphoblastic leukemia/lymphoma (pre-T-LBL/T- ... A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.. Lin ... A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma ... A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma ...
Lymphoid Leukemia, Acute; Lymphomas, Lymphoblastic; Precursor Cell Lymphoblastic Leukemia Lymphoma; Leukemia, Lymphoblastic; ... Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) Show All ,, Key Therapies for Precursor Cell ... Diseases Related to Precursor Cell Lymphoblastic Leukemia-Lymphoma. * Acute Myeloid Leukemia (Acute Myelogenous Leukemia) ... Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) Summary Description: A neoplasm characterized by ...
Precursor cell lymphoblastic leukemia lymphoma Tier 1 H96. Precursor cell lymphoblastic leukemia lymphoma Tier 2 H96. Precursor ... Precursor cell lymphoblastic leukemia lymphoma Tier 1 M96. Precursor cell lymphoblastic leukemia lymphoma Tier 2 M96. Precursor ... Precursor cell lymphoblastic leukemia lymphoma Tier 1 H384. Precursor cell lymphoblastic leukemia lymphoma Tier 1-4 H384. ... Precursor cell lymphoblastic leukemia lymphoma Tier 1 M384. Precursor cell lymphoblastic leukemia lymphoma Tier 1-4 M384. ...
leukemia, myeloid, acute; precursor cell lymphoblastic leukemia-lymphoma Gene Set. Dataset. GAD Gene-Disease Associations ... 11 genes associated with the disease leukemia, myeloid, acute; precursor cell lymphoblastic leukemia-lymphoma in GWAS and other ...
Leukemia, Lymphoblastic; Leukemia, Lymphoid, Acute; Lymphoblastic Leukemia; Lymphoblastic Lymphoma; Lymphocytic Leukemia, Acute ... Lymphoma, Lymphoblastic. On-line free medical diagnosis assistant. Ranked list of possible diseases from either several ... Precursor cell lymphoblastic leukemia-lymphoma (Leukemia, Lymphoblastic; Leukemia, Lymphoid, Acute; Lymphoblastic Leukemia; ... "precursor cell lymphoblastic leukemia-lymphoma"Drugs, active principles and "precursor cell lymphoblastic leukemia-lymphoma" ...
Precursor Cell Lymphoblastic Leukemia-Lymphoma*Precursor Cell Lymphoblastic Leukemia-Lymphoma. *Precursor Cell Lymphoblastic ... "Precursor Cell Lymphoblastic Leukemia-Lymphoma" by people in this website by year, and whether "Precursor Cell Lymphoblastic ... Precursor Cell Lymphoblastic Leukemia-Lymphoma. *Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. *Precursor T-Cell ... "Precursor Cell Lymphoblastic Leukemia-Lymphoma" is a descriptor in the National Library of Medicines controlled vocabulary ...
Precursor cell lymphoblastic leukemia-lymphoma. Clinical trials for drug safety evaluation, please follow the links below to ...
... for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098-1107. ... Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Nicola Gökbuget, Hervé ... Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood, 131(14), 1522- ... Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6( ...
Leukemia. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Leukemia, Lymphoid. Neoplasms by Histologic Type. Neoplasms. ... Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia ... Acute Lymphoblastic Leukemia Biological: KTE-C19 Drug: Fludarabine Drug: Cyclophosphamide Phase 1 Phase 2 ... Diagnosis of Burkitts leukemia/lymphoma according to the World Health Organization (WHO) classification or chronic myelogenous ...
Leukemia. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Leukemia, Lymphoid. Neoplasms by Histologic Type. Neoplasms. ... Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia. The safety and scientific ... Acute Lymphoblastic Leukemia Other: Cytology Specimen Collection Procedure Other: Laboratory Biomarker Analysis ... I. To provide a risk classification scheme for all patients with newly diagnosed acute lymphoblastic leukemia (ALL), which will ...
To clarify the effect of MTHFR C677T on the risk of childhood acute lymphoblastic leukemia … ... C677T and childhood acute lymphoblastic leukemia have provided either controversial or inconclusive results. ... Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics* * Predictive Value of Tests * Risk Factors ... MTHFR C677T polymorphisms and childhood acute lymphoblastic leukemia: a meta-analysis Leuk Res. 2010 Dec;34(12):1596-600. doi: ...
20Division of Leukemia and Lymphoma, Childrens Cancer Center, National Center for Child Health and Development, Setagaya-ku, ... A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia. Leukemia. 2015;29(12):2445-2448. ... B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a heterogeneous disease that can be subdivided according to primary ... ALL: acute lymphoblastic leukemia; BCP-ALL: B-cell precursor ALL; B-others: BCP-ALL without conventional genetic abnormalities ...
Despite many years of meticulous immunophenotyping of childhood acute lymphoblastic leukaemia (ALL) cases the prognostic ... Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy * Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology* ... gender and white cell count at diagnosis except for the very small number with WBC ,20 x 10(9)/l and T cell disease. Those with ... and T cell in 207 (10.7%) cases. Children with T cell disease were significantly more likely to be over the age of 10 years, ...
2001) Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20:5580-5594. ... Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Akinori Yoda, Yuka Yoda, Sabina ... Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Akinori Yoda, Yuka Yoda, Sabina ... 2007) Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood ...
B-precursor lymphoblastic lymphoma. *Morphologically unclassifiable lymphoma. *Absence of both B-cell and T-cell phenotype ... in Treating Young Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma. * Print ... they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma ... chemotherapy regimen is more effective in treating T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. ...
A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell. 1995; 83(2):289-299. PubMed ... Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. Leukemia. 2016; 30( ... B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common malignancy in children and involves uncontrolled ... Imamura T, Yano M, Asai D. IKZF1 deletion is enriched in pediatric B-cell precursor acute lymphoblastic leukemia patients ...
... study is to determine whether Forodesine Hydrochloride is effective in treating patients with relapsed/refractory precursor T- ... Leukemia, Lymphoid. *Precursor Cell Lymphoblastic Leukemia-Lymphoma. *Lymphoma. *Precursor T-Cell Lymphoblastic Leukemia- ... Patients with an unequivocal histologic diagnosis of precursor T-lymphoblastic. leukemia/lymphoma (World Health Organization [ ... Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma ...
A tiling path 33K BAC array was used to study 28 children with acute lymphoblastic leukaemia (ALL) who had normal or failed G- ... Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*. From MEDLINE®/PubMed®, a database of the U.S. National Library of ... 12901975 - The emergence of ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treat.... 1581405 - A randomized ... A tiling path 33K BAC array was used to study 28 children with acute lymphoblastic leukaemia (ALL) who had normal or failed G- ...
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics. Wilms Tumor. Grant Support. ID/Acronym/Agency: CA 34233/CA/NCI NIH ... 2915919 - Are most secondary acute lymphoblastic leukemias mixed acute leukemias?. 7050389 - Monoclonal immunoglobulin of cll ... Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: report of three cases and review of the ... Whereas the development of acute nonlymphocytic leukemia (ANLL) as an SMN is a well-recognized phenomenon, acute lymphoblastic ...
lymphoma. 3. ClinicalTrials. Precursor Cell Lymphoblastic Leukemia-Lymphoma. D054198. EFO:0000220. acute lymphoblastic leukemia ... B-cell acute lymphoblastic leukemia. 3. ClinicalTrials. ClinicalTrials. Leukemia, Plasma Cell. D007952. EFO:0006475. plasma ... T-cell acute lymphoblastic leukemia. 3. ClinicalTrials. ClinicalTrials. Lymphoma, Follicular. D008224. EFO:0000096. neoplasm of ... angioimmunoblastic T-cell lymphoma. 3. ClinicalTrials. Leukemia, Lymphocytic, Chronic, B-Cell. D015451. EFO:0000095. chronic ...
Precursor Cell Lymphoblastic Leukemia-Lymphoma. D054198. EFO:0000220. acute lymphoblastic leukemia. 3. ClinicalTrials. ... Lymphoma, Large-Cell, Anaplastic. D017728. EFO:0003032. anaplastic large cell lymphoma. 1. ClinicalTrials. ... Leukemia. D007938. EFO:0000565. leukemia. 3. ClinicalTrials. ClinicalTrials. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. ... Lymphoma. D008223. EFO:0000574. lymphoma. 2. ClinicalTrials. Neurilemmoma. D009442. EFO:0000760. malignant peripheral nerve ...
Burkitts leukemia or Burkitts lymphoma or primary mediastinal large B-cell lymphoma. or B-precursor lymphoblastic lymphoma or ... Burkitts Lymphoma, Burkitts Leukemia, Mediastinal Neoplasms, Lymphoblastic Lymphoma, Large Cell Anaplastic Lymphoma ... large cell anaplastic lymphoma. - Age > 15 years. - Written informed consent. Exclusion Criteria:. - Serious secondary diseases ... Multicenter Study to Optimise Therapy of B-ALL, Burkitts NHL and High-Grade Non-Hodgkins Lymphoma in Adults (Amend 7). Trial ...
T-Cell Lymphoma , Precursor T-Lymphoblastic Lymphoma/Leukemia Patient Info: Currently in active treatment (initial surgery, ... Patient: Precursor T-Lymphoblastic Lymphoma/Leukemia * Patient Info: Currently in active treatment (initial surgery, receiving ...
T-Cell Lymphoma , Precursor T-Lymphoblastic Lymphoma/Leukemia Patient Info: Newly diagnosed (has not begun treatment), ... Patient: Precursor T-Lymphoblastic Lymphoma/Leukemia * Patient Info: Newly diagnosed (has not begun treatment), Diagnosed: over ...
Blood Cell Count. Bone Marrow Examination. Child, Preschool. Immunophenotyping. Precursor Cell Lymphoblastic Leukemia-Lymphoma ... had acute lymphoblastic leukaemia, 51.8% had acute myeloblastic leukemia and 7.8% were unclassified. Diagnosis was made at less ... than 10 years in 31.6% of cases and 72% of these were the lymphoblastic type. Anaemia [Hb , 11 g/dL was found in 85% of cases, ...
Precursor T-lymphoblastic lymphoma/leukemia The WHO classification subtypes for peripheral B-cell neoplasms are as follows:. * ... Mantle Cell Lymphoma. Diagnosis. Mantle cell lymphoma (MCL) is diagnosed in accordance with the World Health Organization ... of MCLs but is negative in all other B-cell lymphoid neoplasms except Burkitt lymphomas and lymphoblastic lymphomas ... Diffuse Large B-Cell Lymphoma. Diagnosis. In addition to its general guidance on diagnosis of lymphoma, the National ...
  • We demonstrate that SMI-4a, a novel benzylidene-thiazolidine-2, 4-dione small molecule inhibitor of the Pim kinases, kills a wide range of both myeloid and lymphoid cell lines with precursor T-cell lymphoblastic leukemia/lymphoma (pre-T-LBL/T-ALL) being highly sensitive. (nih.gov)
  • All cell lines except for Nalm 6 pre-B-LBL were derived from a myeloid leukemia. (nih.gov)
  • Sharma K, Singh U, Rai M, Shukla J, Gupta V, Narayan G, Kumar S. Interleukin 6 and disease transformation in chronic myeloid leukemia: A Northeast Indian population study. (rush.edu)
  • TSLP is produced by epithelial cells at sites of inflammation, where it activates myeloid dendritic cells and Th2 immune responses ( 18 , 19 ). (pnas.org)
  • Chromosomal Abnormalities and Prognosis in NPM1 -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. (nih.gov)
  • The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (springer.com)
  • Biphenotypic acute leukaemia (BAL) is an uncommon type of leukemia which arises in multipotent progenitor cells which have the ability to differentiate into both myeloid and lymphoid lineages. (wikipedia.org)
  • The cells could display both myeloid lineage and lymphoid or undifferentiated morphology. (wikipedia.org)
  • If the score of only one lineage is higher than 2, the acute leukemia could be acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). (wikipedia.org)
  • Gentuzumab ozogamicin targets CD33, a myeloid lineage antigen, and is approved for acute myeloid leukemia ( 8 ). (aacrjournals.org)
  • Aberrant tyrosine kinase activity plays a critical role in many hematologic disorders, including chronic myeloid leukemia characterized by the constitutive activity of BCR-ABL. (aacrjournals.org)
  • Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the Philadelphia (Ph) chromosome, which results from t(9;22)(q34;q11) balanced reciprocal translocation ( 1 ). (aacrjournals.org)
  • Such group demonstrates expression of stem cell and myeloid markers in conjunction with the T cell antigens. (springer.com)
  • This mutant mouse strain may be useful in studies of myelodysplastic syndromes, precursor T cell lymphoblastic leukemia/lymphoma (pre-T LBL) and acute myeloid leukemia. (jax.org)
  • Precursor lymphoid neoplasms are categorized as B lymphoblastic leukemia/lymphoma and T lymphoblastic leukemia/lymphoma. (hindawi.com)
  • As the name suggests, the cells that proliferate are immature lymphoid cells known as lymphoblasts, which have become halted in their development. (hindawi.com)
  • Bone marrow biopsy and aspirate revealed a hypercellular marrow almost completely replaced by a diffuse infiltrate of large lymphoid cells (Figures 1(a) and 1(b) ) with basophilic cytoplasm, cytoplasmic vacuoles, and large prominent nucleoli (L3/Burkitt lymphoma-like morphology) (Figure 2 ). (hindawi.com)
  • A peripheral smear showed few circulating abnormal lymphoid cells (5%) with the same cytologic features as the cells found in the bone marrow (Figure 3 ). (hindawi.com)
  • A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. (lookfordiagnosis.com)
  • Transcription factor IKZF1 (IKAROS) acts as a critical regulator of lymphoid differentiation and is frequently deleted or mutated in B-cell precursor acute lymphoblastic leukemia. (haematologica.org)
  • B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common malignancy in children and involves uncontrolled expansion of B-lymphoid progenitors in the bone marrow. (haematologica.org)
  • This gene encodes a member of the T cell factor/lymphoid enhancer factor family of transcription factors. (cancerindex.org)
  • Precursor B-cell lymphoblastic leukemia is a form of lymphoid leukemia in which too many B-cell lymphoblasts (immature white blood cells) are found in the blood and bone marrow. (wikipedia.org)
  • Marginal zone lymphoma (including mucosa-associated lymphoid tissue [MALT] lymphoma). (oncolink.org)
  • We now report the development of thymic T cell lymphoblastic lymphomas in transgenic mice in which Stat5a or Stat5b is overexpressed within the lymphoid compartment. (nih.gov)
  • More recently, TdT was detected in transient populations of peripheric cells in young rats and mice (12), The biological function of TdT remains unknown although its biochemical properties and its cellular distribution have suggested a possible role in the differentiation of lymphoid cells and in the generation of the diversity of immunoglobulins (4, 13). (springer.com)
  • Leukemia is preceded by a dramatic expansion of cells resembling hematopoietic stem cells and lymphoid-committed progenitors prior to disease onset, accompanied by a blockage in B-cell differentiation at the early pro-B stage. (biologists.org)
  • Describe the features of follicular center cell (FCC) lymphomas. (brainscape.com)
  • Pediatric-type follicular lymphoma. (oncolink.org)
  • Composite chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma are biclonal lymphomas: a report of two cases. (semanticscholar.org)
  • The FDA approved Yescarta to treat adults (18 and older) with follicular lymphoma that has resisted treatment, or came back, after two other therapies. (ohsu.edu)
  • These phrases were contained in old descriptors which now are subsumed under NON-HODGKINS LYMPHOMA or FOLLICULAR LYMPHOMA. (nih.gov)
  • Investigation revealed chylous effusion secondary to non-Hodgkin lymphoma of the follicular type. (ispub.com)
  • A non-traumatic chylothorax secondary to follicular lymphoma was found and the effusion resolved with infusion of octeotride. (ispub.com)
  • A bone marrow biopsy revealed a non-Hodgkins lymphoma (follicular lymphoma). (ispub.com)
  • Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker? (bioportfolio.com)
  • The incidence of diffuse large B-cell lymphoma increases with age in both males and females. (oncolink.org)
  • The 2 primary immunodeficiency patients presented a T-cell lymphoblastic lymphoma and a diffuse large B-cell lymphoma. (acronymfinder.com)
  • it is very common in BAL patients, most of patients die due to the A low level of red blood cells in the bloodstream: Because the decline of hematopoietic function, need blood transfusion therapy Persistent fever, infection prolonged healing: Diffuse hemorrhage: which is dangerous and might lead to death. (wikipedia.org)
  • Primary composite lymphoma of the larynx, composed of diffuse large B-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified, presenting as left subglottic tracheal fistula, esophageal diverticulum, and neck abscess. (semanticscholar.org)
  • This includes morphological descriptions of cell types like "small cleaved-cell" or "large-cell" or "undifferentiated" and grading such as "high grade" or "diffuse. (nih.gov)
  • Needle biopsy of a retroperitoneal mass revealed diffuse infiltration of lymphoblastic tumor cells. (unboundmedicine.com)
  • A bone marrow biopsy was also obtained ( image ), which showed a diffuse infiltration by tumor cells with a similar morphology as the renal biopsy. (pathologyoutlines.com)
  • The renal biopsy showed a diffuse infiltrate of monotonous blastoid cells obliterating the normal renal architecture. (pathologyoutlines.com)
  • Li-Fraumeni syndrome presenting as precursor B lymphoblastic leukemia mimicking intravascular large B-cell lymphoma. (harvard.edu)
  • Yescarta, Kymriah and Breyanzi are approved for adults with large B-cell lymphoma that resisted two or more therapies or that relapsed. (ohsu.edu)
  • Within the B-cell and T-cell categories, two subdivisions are recognized: precursor neoplasms, which correspond to the earliest stages of differentiation, and more mature differentiated neoplasms. (medscape.com)
  • Source: Gamma delta T-cell neoplasms: a clinicopathological study of 11 cases. (lymphomation.org)
  • Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. (nhi.no)
  • Describe the features of B small lymphocytic lymphoma/B cell CLL. (brainscape.com)
  • Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. (semanticscholar.org)
  • We report on 2 composite lymphomas occurring in elderly patients, morphologically characterized by the combination of peripheral T-cell lymphoma (PTCL) unspecified and B-cell small lymphocytic lymphoma. (semanticscholar.org)
  • In sub-Saharan Africa, the high incidence of Epstein-Barr virus (EBV)-induced Burkitt lymphoma/leukemia is tenfold to twentyfold higher, resulting in a much higher incidence of NHL. (oncolink.org)
  • The incidence of NHL is higher in whites than in African Americans, and Burkitt lymphoma/leukemia is more common in non-Hispanic whites (3.2 cases/million person-years) than in Hispanic whites (2.0 cases/million person-years). (oncolink.org)
  • A review of Surveillance, Epidemiology, and End Results (SEER) data revealed that 2.5 cases per 1 million person-years of Burkitt lymphoma/leukemia were diagnosed in the United States between 1992 and 2008, with more cases in males than in females (3.9:1.1). (oncolink.org)
  • Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. (cancerindex.org)
  • Anaplastic large cell lymphoma (ALCL) is a peripheral T-cell lymphoma presenting mostly in children and young adults. (cancerindex.org)
  • Pastorello RG, D'Almeida Costa F, Osório CABT, Makdissi FBA, Bezerra SM, de Brot M, Campos AHJFM, Soares FA, Vassallo J. Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report. (harvard.edu)
  • brentuximab-vedotin, an ADC targeting CD30, is approved for the treatment of tumors arising from these cell populations, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma ( 2, 5, 6 ). (aacrjournals.org)
  • Patients could undergo allogeneic hematopoietic stem-cell transplantation any time after cycle 1. (bloodjournal.org)
  • Depending on the condition, hematology specialists may treat a patient with a blood transfusion, stem cell transplantation, bone marrow transplant, radiotherapy, anticoagulation therapy or medication. (vitals.com)
  • Determine whether this treatment regimen can mobilize sufficient hematopoietic stem cells (CD34) for subsequent stem cell transplantation in minimally pretreated, low-risk patients. (bioportfolio.com)
  • Heavily pretreated, high-risk patients who achieve a complete response are eligible for stem cell transplantation. (bioportfolio.com)
  • Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative, Allogeneic Peripheral-Blood Stem-Cell Transplantation," The New England Journal of Medicine, Sep. (freepatentsonline.com)
  • A blood-forming stem-cell transplantation is highly recommended. (wikipedia.org)
  • The authors report the results of the first-in-human clinical trial of a novel interleukin-15 (IL-15) fusion protein to promote graft-versus-leukemia without enhancing graft-versus-host disease in patients with hematologic malignancies who relapsed after allogeneic stem cell transplantation. (prnewswire.com)
  • To estimate levels of CD20 expression at baseline, during treatment with dexamethasone-containing chemotherapy and following rituximab treatment in Block 1 of remission induction therapy for relapsed precursor B-cell ALL. (clinicaltrials.gov)
  • Remission induction for all participants consists of three blocks of therapy, wherein the first block is a novel immunotherapy regimen that includes cytotoxic chemotherapy, rituximab and infusion of haploidentical natural killer (NK) cells. (clinicaltrials.gov)
  • Participants with lymphoma must be in complete remission at the end of Block III. (clinicaltrials.gov)
  • Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase-polymerase chain reaction or flow cytometry. (bloodjournal.org)
  • In this open-label, single-arm study, adults with B-cell precursor ALL in hematologic complete remission with MRD (≥10 −3 ) received blinatumomab 15 µg/m 2 per day by continuous IV infusion for up to 4 cycles. (bloodjournal.org)
  • To determine the rate of complete remission for T lymphoblastic leukemia/lymphoma relapsed or refractory patients. (knowcancer.com)
  • B-cell precursor ALL who are in remission but still have minimal residual disease (MRD). (lls.org)
  • A stem cell transplant may be an option for some people with precursor lymphoblastic lymphoma who go into remission after chemotherapy. (cancer.ca)
  • The therapy has led to long-term remission for children and adults with some types of leukemia and lymphoma. (ohsu.edu)
  • The patient achieved complete remission by an induction therapy for acute lymphoblastic leukemia, underwent allogeneic bone marrow transplantation, and has remained in complete remission for more than 3 years. (unboundmedicine.com)
  • Management of adult patients with acute lymphoblastic leukemia in first complete remission: Systematic review and meta-analysis. (nhi.no)
  • Intractable epilepsy in patients treated for childhood acute lymphocytic leukemia. (rush.edu)
  • Meeker TC, Hardy D, Willman C, Hogan T, Abrams J. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. (springer.com)
  • Asparaginase is a prescription medicine approved for use with other chemotherapy drugs to treat a certain type of acute lymphocytic leukemia (ALL is a type of cancer of the white blood cells). (rxwiki.com)
  • The aim of this study was to evaluate the relationship between body composition, metabolic profile, adipokines, and carotid intima-media thickness (cIMT) in young survivors of childhood acute lymphocytic leukemia (ALL). (dovepress.com)
  • Selectively increased expression and functions of chemokine receptor CCR9 on CD4+ T cells from patients with T-cell lineage acute lymphocytic leukemia. (semanticscholar.org)
  • Composite Hodgkin lymphoma and chronic lymphocytic leukemia: a rare case. (semanticscholar.org)
  • We report the first characterization at the immunological and molecular level of 12 cases of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL) from Tunisia. (cnrs.fr)
  • Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma , Spina et al. (prnewswire.com)
  • Thalhammer-Scherrer R, Mitterbauer G, Simonitsch I, Jaeger U, Lechner K, Schneider B, Fonatsch C, Schwarzinger I. The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination. (springer.com)
  • Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. (ac.be)
  • The rearrangement of MLL are related with different kinds of aggressive acute leukemias. (wikipedia.org)
  • Elderly patients with adverse cytogenetic abnormalities and high white blood cell count have a very poor prognosis. (hindawi.com)
  • The prognosis for adults with precursor B-cell acute lymphoblastic leukemia (B-ALL) remains poor, in part from a lack of therapeutic targets. (pnas.org)
  • Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of malignancies of different biology and prognosis. (medscape.com)
  • researchers have been able to isolate pure tumor cells at all stages. (jci.org)
  • Cancer stem cells (CSCs) constitute a sub-population of tumor cells that possess stem cell properties, such as self-renewal and the ability of differentiation. (cancerindex.org)
  • RATIONALE: Treating lymphocytes in the laboratory may help the lymphocytes kill more tumor cells when they are put back in the body. (bioportfolio.com)
  • Also shown is the CD4/CD8 profile of subcutaneous cervical lesions in a RAG/γc double KO mouse 3 wk after subcutaneous injection of fresh tumor cells (panels d and h). (nih.gov)
  • tumor cells preferentially infiltrate the sinusoids of the splenic red pulp, liver, and bone marrow. (lymphomation.org)
  • The tumor cells have a nonactivated cytotoxic T-cell immunophenotype and frequently carry a recurrent cytogenetic abnormality, isochromosome 7q. (lymphomation.org)
  • Tumor cells have higher rates of glucose uptake and aerobic glycolysis to meet energy demands for proliferation and metastasis. (medsci.org)
  • Here, we demonstrate that Pim-2 is required for glycolysis and energy production in colorectal tumor cells. (medsci.org)
  • Our results show that Pim-2 is highly expressed in colorectal tumor cells, and may be induced by nutrient stimulation. (medsci.org)
  • While knockdown of Pim-2 decreased energy production in colorectal tumor cells and increased their susceptibility to apoptosis. (medsci.org)
  • Our findings suggest that Pim-2-mediated aerobic glycolysis is critical for monitoring Warburg effect in colorectal tumor cells, highlighting Pim-2 as a potential metabolic target for colorectal tumor therapy. (medsci.org)
  • Immunophenotyping of selected hematologic disorders--focus on lymphoproliferative disorders with more than one malignant cell population. (semanticscholar.org)
  • Cutaneous lymphomas comprise a heterogeneous group of lymphoproliferative disorders with skin involvement and are classified as a subgroup of non-Hodgkin lymphomas. (scielo.br)
  • To estimate the 3-year survival rate of participants with first relapse or primary refractory precursor B-cell ALL and lymphoblastic lymphoma treated with risk-directed therapy. (clinicaltrials.gov)
  • The primary objectives of this study are to evaluate the safety and efficacy of KTE-C19 in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL). (clinicaltrials.gov)
  • This randomized phase I trial is studying the side effects and best dose of two different schedules of sorafenib in treating patients with refractory or relapsed acute leukemia, myelodysplastic syndromes, or blastic phase chronic myelogenous leukemia. (clinicaltrials.gov)
  • I. Determine the maximum tolerated dose of sorafenib when administered in two different schedules in patients with refractory or relapsed acute leukemia, myelodysplastic syndromes, or blastic phase chronic myelogenous leukemia. (clinicaltrials.gov)
  • This phase II trial is studying how well panobinostat works in treating patients with relapsed or refractory non-Hodgkin lymphoma. (mayo.edu)
  • PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have refractory or relapsed Hodgkin's lymphoma. (bioportfolio.com)
  • Determine the response rate (overall and within strata) in both minimally pretreated, low-risk and heavily pretreated, high-risk children with refractory or relapsed Hodgkin's lymphoma treated with ifosfamide and vinorelbine with filgrastim (G-CSF). (bioportfolio.com)
  • Residual, refractory or relapsed cancer is treated by immunostimulation in the presence of allogeneic immune effector cells, optimally in combination with radiation therapy. (freepatentsonline.com)
  • This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). (fredhutch.org)
  • First, genes involved in normal B-cell development (e.g. (pnas.org)
  • The encoded protein contains a high mobility group-box DNA binding domain and participates in the regulation of cell cycle genes and cellular senescence. (cancerindex.org)
  • CAR T-cell therapy is a gene therapy because genes in the patient's T cells are reprogrammed to make CARs. (ohsu.edu)
  • The second study uses microdissection and single-cell sequencing to establish the importance of JAK-STAT pathway genes in cHL, an observation that is mirrored in the ctDNA study. (prnewswire.com)
  • PRDM14 functions in embryonic stem cell (ESC) maintenance to promote the expression of pluripotency-associated genes while suppressing differentiation genes. (biologists.org)
  • We report the occurrence of T cell receptor (TCR) beta and/or gamma gene rearrangements in two precursor B-ALL patients who had normally rearranged Ig genes. (cnrs.fr)
  • This test detects characteristic changes (rearrangements) in specific genes in T-cells. (labtestsonline.org)
  • Genome-wide gene expression analysis of leukemic samples from precursor B-cell ALL patients (n=18) identified a set of genes differentially expressed in blasts at diagnosis day 0 (d0) and persisting on day 8 (d8). (uni-regensburg.de)
  • Bio Rad ( The T Cell Marker, CD3 Antigen and Antibodies, 2016). (freepatentsonline.com)
  • Stat5 synergizes with T cell receptor/antigen stimulation in the development of lymphoblastic lymphoma. (nih.gov)
  • The T cells are sent to a lab where they are genetically modified to make the chimeric antigen receptor, or CAR. (ohsu.edu)
  • Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas , Scarfò et al. (prnewswire.com)
  • These preclinical studies support the use of CD37 as a target antigen for novel chimeric antigen receptor T-cell reagents. (prnewswire.com)
  • They demonstrate activity against B- and T-cell lymphomas both by single-antigen targeting and by dual-specific therapy in combination with anti-CD19. (prnewswire.com)
  • Inotuzumab ozogamicin targets CD22, a B-cell lineage antigen, and is approved for B-cell precursor acute lymphoblastic leukemia ( 7 ). (aacrjournals.org)
  • Polatuzumab vedotin targets CD79b, an antigen expressed in B cells and B-cell lymphoma ( 9 ). (aacrjournals.org)
  • To date, case-control studies on the association between methylenetetrahydrofolate reductase (MTHFR) C677T and childhood acute lymphoblastic leukemia have provided either controversial or inconclusive results. (nih.gov)
  • To clarify the effect of MTHFR C677T on the risk of childhood acute lymphoblastic leukemia, a meta-analysis of all case-control observational studies was performed. (nih.gov)
  • The random effects (RE) model showed that the 677T allele was not associated with a decreased susceptibility risk of childhood acute lymphoblastic leukemia compared with the C allele [OR=0.96, 95% confidence interval (CI) (0.88-1.04), P=0.34]. (nih.gov)
  • Although MTHFR C677T was associated with increased risks of colorectal cancer, leukemia, and gastric cancer, our pooled data suggest no evidence for a major role of MTHFR C677T in the carcinogenesis of childhood acute lymphoblastic leukemia. (nih.gov)
  • In childhood acute lymphoblastic leukemia (ALL), persistence of leukemic blasts during therapy is of crucial prognostic significance. (uni-regensburg.de)
  • Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. (springer.com)
  • By 14 months of age a subset of hemizygotes succumbs to malignant leukemia or severe anemia and leucopenia. (jax.org)
  • Pleural fluid cytology was negative for malignant cells. (ispub.com)
  • It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. (lookfordiagnosis.com)
  • Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. (clinicaltrials.gov)
  • Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. (mayo.edu)
  • Giving more than one drug (combination chemotherapy) may kill more cancer cells. (mayo.edu)
  • The involvement of childhood cancer is relatively rare, with relevant incidence rates of some cancers such as Acute Lymphoblastic Leukemia (ALL) and Wilms Tumor (WT). (usp.br)
  • Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (mayo.edu)
  • The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer. (lls.org)
  • Correlation of HIWI and HILI Expression with Cancer Stem Cell Markers in Colorectal Cancer. (cancerindex.org)
  • The aim of the study was to evaluate the clinical significance of the HIWI and HILI expression and its relationship with cancer stem cells markers in 72 patients with colorectal carcinoma (CRC). (cancerindex.org)
  • The expression level of HIWI and HILI and cancer stem cells markers in paired cancerous and non-cancerous tissues was measured by real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. (cancerindex.org)
  • cancer cells, either by killing the cells or by stopping them from dividing. (bioportfolio.com)
  • Giving fludarabine and cyclophosphamide together with thalidomide may kill more cancer cells. (bioportfolio.com)
  • cancer cells from dividing so they stop growing or die. (bioportfolio.com)
  • cancer cells. (bioportfolio.com)
  • RATIONALE: Drugs used in chemotherapy, such as gemcitabine and vinorelbine, use different ways to stop cancer cells from dividing so they stop growing or die. (bioportfolio.com)
  • Cancer is when cells in the body change and grow out of control. (hopkinsmedicine.org)
  • Cancer is made up of abnormal cells that grow even though your body doesn't need them. (hopkinsmedicine.org)
  • If cancer cells are in your body long enough, they can grow into, or invade, nearby areas. (hopkinsmedicine.org)
  • Lymphoma is a kind of cancer that starts in the lymphatic system. (hopkinsmedicine.org)
  • T-cells can also kill some cancer cells. (hopkinsmedicine.org)
  • With Hodgkin lymphoma, cancer cells only make up a small part of the cells in a cancerous lymph node. (hopkinsmedicine.org)
  • The cancer cells are usually special cells called Reed-Sternberg cells. (hopkinsmedicine.org)
  • In non-Hodgkin lymphoma, cancer cells make up most of a tumor. (hopkinsmedicine.org)
  • High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition. (nih.gov)
  • High dose vitamin C inhibits proliferation of breast cancer cells through reducing glycolysis and protein synthesis]. (nih.gov)
  • Cancer Cell. (springer.com)
  • Cyclophosphamide is a prescription medicine used alone, or in combination with other medications to treat several types of cancer including lymphoma, leukemia, ovarian, and breast cancer. (rxwiki.com)
  • It works by interfering with the growth of rapidly multiplying cancer cells, by a process known as cross-linking tumor cell DNA. (rxwiki.com)
  • This specific enzyme works by interfering with natural substances necessary for cancer cell growth. (rxwiki.com)
  • a type of cancer of the white blood cells). (rxwiki.com)
  • It works by slowing or stopping the growth of cancer cells in your body. (rxwiki.com)
  • This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood non-Hodgkin lymphoma. (oncolink.org)
  • And the best news of all is that I just got the results of the 3 month bone marrow and my cells are 100% my sisters, with no evidence of cancer! (lymphomation.org)
  • T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer that arises from clonal expansion of transformed T-cell precursors. (semanticscholar.org)
  • Symptoms caused by blood cancer cells infiltration into tissues: Swollen lymph nodes Joint pain Swelling of the gums Enlargement of the liver and spleen Headache and vomiting: blood cancer infiltration into the wear performance of the central nervous system. (wikipedia.org)
  • In the analysis of a real-world microarray dataset, the two Global Tests gave markedly different results, compared to SAM-GS, in identifying pathways whose gene expressions are associated with p53 mutation in cancer cell lines. (nih.gov)
  • CAR T-cell therapy is an inventive treatment that takes T cells from the patient's body and modifies them to destroy cancer cells. (ohsu.edu)
  • It's best handled at centers - such as the Knight Cancer Institute - with deep experience doing stem cell and bone marrow transplants. (ohsu.edu)
  • Receptor" means it can bind to a cancer cell, like a key fitting in a lock. (ohsu.edu)
  • This protein binds to specific proteins on the surface of cancer cells. (ohsu.edu)
  • That equips the modified T cells to target and kill the cancer cells. (ohsu.edu)
  • Once in the patient's bloodstream, the CAR T cells multiply and may be able to destroy all the cancer cells. (ohsu.edu)
  • The reprogrammed cells may stay in the body to fight cancer for years. (ohsu.edu)
  • Donor cells may be more effective at fighting cancer. (ohsu.edu)
  • This aggressive blood cancer is the most common type of non-Hodgkin lymphoma. (ohsu.edu)
  • however, aberrant expression is associated with tumor initiation in a wide variety of human cancers, including breast cancer and leukemia. (biologists.org)
  • Cancer cell energy metabolism deviates significantly from that of normal tissues. (medsci.org)
  • However, cancer cells perform higher rates of aerobic glycolysis with products of pyruvate and lactate, known as Warburg effect [ 2 ]. (medsci.org)
  • It is thought that cancer cells take this metabolic transformation not only to meet energy demand but also to maintain the redox homeostasis [ 3 ]. (medsci.org)
  • Due to the preference of aerobic glycolysis, cancer cells can be selectively targeted by disruption of their glucose metabolism [ 5 - 7 ]. (medsci.org)
  • Targeted killing of cancer cells without toxicity to normal cells, is one of the most significant considerations in cancer chemotherapy. (medsci.org)
  • These glycolytic factors are consistently and significantly expressed in cancer cells. (medsci.org)
  • Thus, factors that involve mTORC1 signaling activation may have potential to modulate aerobic glycolysis in cancer cells. (medsci.org)
  • Most non-Hodgkin lymphomas in the U.S. are B-cell lymphomas (about 85%), according to the American Cancer Society. (labtestsonline.org)
  • Precision Cancer Medicine Precision medicine enables cancer specialists to identify and target cancer cells. (osu.edu)
  • His work also explores the development of novel/improved strategies for radiosensitization of cancer cells in an effort to protect normal cells and achieve a better therapeutic ratio. (osu.edu)
  • Dr. Jacob has co-authored more than 25 articles appearing in well-known science journals such as Molecular Cell, Cancer Research, Radiation Research and Molecular Biology of the Cell. (osu.edu)
  • Acute lymphoblastic leukemia (ALL) is the most common cancer in children and adolescents in the United States. (cdc.gov)
  • However, we find that a TCR is required for thymic egress and development of peripheral murine tumours, yet this TCR must be downregulated for T-cell lymphomagenesis. (cancerindex.org)
  • Children affected by ALCL may thus harbour thymic lymphoma-initiating cells capable of seeding relapse after chemotherapy. (cancerindex.org)
  • B-LBL and T-LBL can be considered either a lymphoma or leukemia, depending on how many areas of bone marrow have lymphoblasts in them. (cancer.ca)
  • If less than 25% of cells in the bone marrow are lymphoblasts, it is considered a lymphoblastic lymphoma. (cancer.ca)
  • Lymphoma may also spread to the bone marrow and to other organs in the body. (hopkinsmedicine.org)
  • The number of blood cells in your bone marrow. (rxwiki.com)
  • HSTCL is a rare aggressive type of extranodal lymphoma characterized by hepatosplenomegaly, bone marrow involvement, and peripheral blood cytopenias. (lymphomation.org)
  • Kroft, Steven H. / Precursor B-cell lymphoblastic lymphoma : A study of nine cases lacking blood and bone marrow involvement and review of the literature . (elsevier.com)
  • Bone marrow neoplastic niche in leukemia. (semanticscholar.org)
  • Our team's exceptional expertise, on our Bone Marrow and Stem Cell Transplant page. (ohsu.edu)
  • Lymphoblasts in bone marrow were positive for CD10 and CD19 but negative for CD20, surface immunoglobulin, and T-cell antigens. (unboundmedicine.com)
  • Because the cells were immunoreactive for CD79a, CD10, and terminal deoxynucleotidyl transferase, the patient was diagnosed as having precursor B-lymphoblastic lymphoma (which is rare in adults) with bone marrow involvement. (unboundmedicine.com)
  • The bone marrow biopsy showed a similar population of cells replacing most of the marrow. (pathologyoutlines.com)
  • Hemizygotes develop myelodysplastic syndromes (hematopoietic stem cell disorder) with peripheral blood cytopenia and dysplasia and normocellular to hypercellular bone marrow. (jax.org)
  • Treatment will consist of chemotherapy for SR participants, and chemotherapy followed by hematopoietic stem cell transplant (HSCT) for HR in first relapse. (clinicaltrials.gov)
  • The first block is a novel immunotherapy regimen that includes chemotherapy, rituximab and infusion of haploidentical natural killer (NK) cells. (clinicaltrials.gov)
  • The general treatment plan will consist of chemotherapy for standard-risk participants and chemotherapy followed by HSCT for high risk participants in first relapse of B-precursor ALL or lymphoblastic lymphoma. (clinicaltrials.gov)
  • This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. (mayo.edu)
  • It is not yet known which combination chemotherapy regimen is more effective in treating T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. (mayo.edu)
  • Determine the response rate in patients with angioimmunoblastic T-cell lymphoma after chemotherapy comprising fludarabine and cyclophosphamide. (bioportfolio.com)
  • Chemotherapy is the main treatment for lymphoblastic lymphomas. (cancer.ca)
  • Patients undergo peripheral blood stem cell (PBSC) collection during hematopoietic recovery after the second course of chemotherapy. (bioportfolio.com)
  • Doctors may give the patient a short course of chemotherapy before giving them the CAR T cells in an IV drip. (ohsu.edu)
  • PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells , Kahn et al. (prnewswire.com)
  • Here we present a model of peripheral ALCL pathogenesis where the malignancy is initiated in early thymocytes, before T-cell receptor (TCR) β-rearrangement, which is bypassed in CD4/NPM-ALK transgenic mice following Notch1 expression. (cancerindex.org)
  • Although HSTCL is the prototype peripheral T-cell lymphoma expressing the γδ T-cell receptor, non-HSTCL proliferations of γδ T cells can involve other extranodal sites, mainly skin and mucosa. (lymphomation.org)
  • Chest radiographs may reveal signs of pneumonia and/or a prominent mediastinal mass in some cases of T-cell acute lymphoblastic leukemia (ALL). (medscape.com)
  • Childhood NHL is more common in males than in females, with the exception of primary mediastinal B-cell lymphoma, in which the incidence is almost the same in males and females. (oncolink.org)
  • have coined a 'thoracic sandwich sign' in reference to anterior-mediastinal lymphadenopathy encompassing the brachiocephalic vein on chest CT in a patient with T-cell lymphoblastic lymphoma . (acronymfinder.com)
  • This mutant mouse strain may be useful in studies of myelodysplastic syndromes and leukemia. (jax.org)
  • A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. (nih.gov)
  • Careful morphologic study and immunophenotyping by flow cytometry or immunohistochemistry is helpful to arrive at the correct diagnosis, and to avoid confusion with other small blue cell tumors which may involve the kidney, such as Wilm s tumor ( J Pediatr Hematol Oncol 2008;30:471 ) , small cell carcinoma or Ewing s sarcoma/primitive neuroectodermal tumor. (pathologyoutlines.com)
  • Acute lymphoblastic leukemia/lymphoma is rare in the adult population, and the lymphoblasts that are characteristic of the disease show a spectrum of differentiation and have varied cytogenetic alterations. (hindawi.com)
  • similar to small lymphocytic lymphomas but shows plasmacytoid differentiation. (brainscape.com)
  • When a large biopsy or resection specimen is available for review, the morphologic differentiation between thymoma and T-cell ALL/LBL, in general, is straightforward. (humpath.com)
  • Differentiation of thymoma from T-cell ALL/LBL based on histologic examination can be confounded further by a thymoma that has a predominance of lymphocytes . (humpath.com)
  • A direct comparison with normal B cells, which are largely therapy resistant, confirmed the differentiation shift at the mRNA (n=10) and protein (n=109) levels. (uni-regensburg.de)
  • As regards type of leukaemia, 40.4% had acute lymphoblastic leukaemia, 51.8% had acute myeloblastic leukemia and 7.8% were unclassified. (who.int)
  • Array-CGH reveals hidden gene dose changes in children with acute lymphoblastic leukaemia and a normal or failed karyotype by G-banding. (biomedsearch.com)
  • A tiling path 33K BAC array was used to study 28 children with acute lymphoblastic leukaemia (ALL) who had normal or failed G-banded karyotypes. (biomedsearch.com)
  • Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia. (springer.com)
  • Sawinska M, Ladon D. Mechanism, detection and clinical significance of the reciprocal translocation t(12;21)(p12;q22) in the children suffering from acute lymphoblastic leukaemia. (springer.com)
  • A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). (springer.com)
  • Acute lymphoblastic leukaemia. (nhi.no)
  • Prognostic factors in adult acute lymphoblastic leukaemia. (nhi.no)
  • Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. (nhi.no)
  • The cells show L3 morphology (Burkitt-like lymphoma) with coexpression of TdT and surface light chains in addition to an MYC gene translocation and Philadelphia chromosome. (hindawi.com)
  • Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. (springer.com)
  • The molecular consequence of the Ph chromosome is the generation of the BCR-ABL oncogene that encodes for the chimeric BCR-ABL oncoprotein, with constitutive kinase activity that promotes the growth advantage of leukemic cells ( 2 ). (aacrjournals.org)
  • Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia. (nhi.no)
  • Multiple myeloma is a monoclonal tumor of plasma cells, and its development is preceded by a premalignant tumor with which it shares genetic abnormalities, including universal dysregulation of the cyclin D/retinoblastoma (cyclin D/RB) pathway. (jci.org)
  • Multiple myeloma (MM) is an age-dependent monoclonal tumor of BM plasma cells (PCs). (jci.org)
  • abstract = "We describe 9 cases of precursor B-cell lymphoblastic lymphoma (LYL) without evidence of marrow or blood involvement. (elsevier.com)
  • Precursor lymphoblastic lymphomas start when immature lymphocytes (called lymphoblasts) become abnormal during the earliest stages of their development. (cancer.ca)
  • B cells and T cells are types of lymphocytes. (cancer.ca)
  • B-lymphocytes (B-cells). (hopkinsmedicine.org)
  • T-lymphocytes (T-cells). (hopkinsmedicine.org)
  • They can be grouped by the type of lymphocytes they start in: B-cells or T-cells. (hopkinsmedicine.org)
  • in these cases, the cells were characterized as precursors of T or B lymphocytes (7-11). (springer.com)
  • T cells are lymphocytes - a type of white blood cell that fights infection as part of the immune system. (ohsu.edu)
  • Three patients were classified as having primary cutaneous lymphoma, while in six the disease was systemic with cutaneous involvement. (scielo.br)
  • No deaths occurred in any of the children with primary cutaneous lymphoma. (scielo.br)
  • They can only be considered primary cutaneous lymphomas (PCL) when the initial presentation is in the skin and there is no evidence of extracutaneous involvement at diagnosis, following complete staging. (scielo.br)
  • Symptomatic AVN have been reported in 1-17% of children with acute lymphoblastic leukemia (ALL) during treatment or thereafter although an incidence of up to 72% of asymptomatic AVN has been detected with systematic screening by magnetic resonance imaging (MRI). (minervamedica.it)
  • Patients with clinical evidence of active central nervous system (CNS) leukemia. (knowcancer.com)
  • The Working Formulation, originally proposed in 1982, classified and grouped lymphomas by morphology and clinical behavior (ie, low, intermediate, or high grade) with 10 subgroups labeled A to J. (medscape.com)
  • Acute lymphoblastic leukemia (ALL) is a heterogeneous disease at the demographic, clinical and genetic levels. (haematologica.org)
  • These γδ T-cell lymphomas display marked heterogeneity in clinical and histologic features. (lymphomation.org)
  • Therefore, we investigated the clinical relevance of 13 recurrent genetic alterations in 204 children treated uniformly for relapsed B-cell precursor ALL according to the ALL-REZ BFM 2002 protocol. (uni-regensburg.de)
  • Our doctors helped lead the clinical trial showing that CAR T-cell therapy for lymphoma not only extends survival but may improve quality of life after treatment. (ohsu.edu)
  • The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome. (springer.com)
  • The objective of this study was to describe the clinical course of children with skin manifestations of lymphoma being followed-up at the hematology department of the Teaching Hospital of the Federal University of Minas Gerais. (scielo.br)
  • This information, along with clinical signs and symptoms and results of other laboratory tests, can help clarify a person's diagnosis, or evaluate for persistent, residual, or recurrent lymphoma. (labtestsonline.org)
  • Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma. (nhi.no)
  • Patients with an unequivocal histologic diagnosis of precursor T-lymphoblastic leukemia/lymphoma (World Health Organization [WHO] classification). (knowcancer.com)
  • This research trial studies a risk-based classification system for patients with newly diagnosed acute lymphoblastic leukemia. (clinicaltrials.gov)
  • I. To provide a risk classification scheme for all patients with newly diagnosed acute lymphoblastic leukemia (ALL), which will be used to assign treatment on Children?s Oncology Group (COG) frontline ALL treatment studies. (clinicaltrials.gov)
  • This classification divides NHL into two groups: those of B-cell origin and those of T-cell/natural killer (NK)-cell origin. (medscape.com)
  • The WHO modification of the REAL classification of NHL is based on morphology and cell lineage. (medscape.com)
  • Before 2008, the diagnosis of BAL was based on a score system proposed by the European Group for the Immunological Classification of Leukemias (EGIL) which could differentiate from other kinds of acute leukemia. (wikipedia.org)
  • The old classification system for lymphomas, was discarded for a simpler model. (nih.gov)
  • This is the current update and revision on the WHO classification of acute lymphoblastic leukemias. (springer.com)
  • After treatment with blinatumomab in a population of patients with MRD-positive B-cell precursor ALL, a majority achieved a complete MRD response, which was associated with significantly longer RFS and OS compared with MRD nonresponders. (bloodjournal.org)
  • This study reports high rates of response (78%) and prolonged survival with blinatumomab immunotherapy for adults with minimal residual disease-positive precursor B-cell acute lymphoblastic leukemia. (prnewswire.com)
  • Most of biphenotypic leukemia in children is due to the rearrangement of MLL Besides them, other gene abnormalities has been reported. (wikipedia.org)
  • Lymphoblastic lymphomas are an uncommon, but fast-growing (aggressive), type of non-Hodgkin lymphoma (NHL). (cancer.ca)
  • With non-Hodgkin lymphoma, cells in the lymphatic system grow out of control. (hopkinsmedicine.org)
  • About 85% of people with non-Hodgkin lymphoma in the U.S. have B-cell. (hopkinsmedicine.org)
  • Non-Hodgkin lymphoma is different from Hodgkin lymphoma. (hopkinsmedicine.org)
  • Hodgkin and non-Hodgkin lymphoma also differ in the way they spread and in how they are treated. (hopkinsmedicine.org)
  • Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma. (oncolink.org)
  • Lymphoma (Hodgkin lymphoma and NHL) is the third most common childhood malignancy, and NHL accounts for approximately 7% of cancers in children younger than 20 years in high-income countries. (oncolink.org)
  • These two papers elucidate the molecular landscape of classical Hodgkin lymphoma (cHL). (prnewswire.com)
  • 3. Mehta A, Gulati K, Jain M, Gulati S. Non-Hodgkin lymphoma in a child presenting as nephromegaly and acute renal failure. (pathologyoutlines.com)
  • From 1981 to 2007, 100 children with non-Hodgkin lymphomas were admitted to the Hematology Unit of the Federal University of Minas Gerais Teaching Hospital. (scielo.br)
  • Lymphomas involve the skin either primarily or secondarily and are classified as a subgroup of non- Hodgkin lymphomas (NHL). (scielo.br)
  • Cutaneous T-cell lymphomas constitute a heterogenous group of lymphoproliferative diseases characterized by a clonal expansion of mature postthymic T-cells that infiltrate the skin. (scielo.br)
  • Cutaneous B-cell lymphomas are rare in children except in the uncommon cases of precursor B-cell lymphoblastic lymphoma (B-LBL) in which the initial manifestation of the disease is in the skin. (scielo.br)
  • T-cells are able to find viral proteins in a virus-infected cell and then destroy the infected cell. (hopkinsmedicine.org)
  • T-cells also send out proteins called cytokines. (hopkinsmedicine.org)
  • These proteins signal other types of white blood cells to the infected area. (hopkinsmedicine.org)
  • Signal transducer and activator of transcription (STAT) proteins are latent transcription factors that mediate a wide range of actions induced by cytokines, interferons, and growth factors.The rate of lymphoma induction was markedly enhanced by immunization or by the introduction of TCR transgenes.These data demonstrate the oncogenic potential of dysregulated expression of a STAT protein that is not constitutively activated, and that TCR stimulation can contribute to this process. (nih.gov)
  • As a consequence, the GRB2/GAB2/SOS complex causes constitutive activation of the RAS downstream pathway, thereby activating mitogen-activated protein (MAP) extracellular signal-regulated kinase (ERK)1/2 (MEK) and MAP kinase proteins and resulting in abnormal cell proliferation. (aacrjournals.org)
  • Tjønnfjord GE, Gedde-Dahl T, Heldal D, Brinch L. Treatment outcome in adults with acute lymphoblastic leukemia: 50% long-term disease-free survival. (nhi.no)
  • Human and mouse leukemic cell lines were incubated with the indicated concentrations of SMI-4a for 24 hours in serum-free medium and then viable cells were quantitated by trypan blue exclusion. (nih.gov)
  • B) Human non-T leukemic cell lines. (nih.gov)
  • C) The murine leukemic cell lines tested were established from pre-T-LBL (12/1. (nih.gov)
  • Furthermore, we discuss different mechanisms by which IKZF1 alterations impose therapy resistance on leukemic cells, including enhanced cell adhesion and modulation of glucocorticoid response. (haematologica.org)
  • Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia. (semanticscholar.org)
  • PRDM14-induced leukemic cells contain high levels of activated NOTCH1 and downstream NOTCH1 targets, including MYC and HES1, and are sensitive to pharmacological inhibition of NOTCH1 with the γ-secretase inhibitor DAPT. (biologists.org)
  • Finally, the abnormal pathways that sustain the self-renewal of leukemic stem cells are described as possible targets to completely eradicate leukemic clones. (aacrjournals.org)
  • This type of lymphoma tends to spread first to the lymph nodes near that organ or to sites other than the lymph nodes. (hopkinsmedicine.org)
  • The B acute lymphoblastic leukemia/lymphoma (ALL) is further classified into B-ALL not otherwise specified or those with recurrent genetic abnormalities. (hindawi.com)
  • From the outside, from within: Biological and therapeutic relevance of signal transduction in T-cell acute lymphoblastic leukemia. (semanticscholar.org)
  • Many of the leukemia terms have undergone name changes as immunophenotypic and molecular biological techniques have made diagnosis more precise. (nih.gov)
  • Of the seven FDA-approved ADCs, four target lineage-specific hematologic antigens that are not markedly differentially expressed in neoplastic versus nonneoplastic cells. (aacrjournals.org)
  • In addition, treatment of these cells with SMI-4a was found to induce phosphorylation of extracellular signal-related kinase1/2 (ERK1/2), and the combination of SMI-4a and a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor was highly synergistic in killing pre-T-LBL cells. (nih.gov)
  • IKZF1 gene defects are associated with inferior treatment outcome in both childhood and adult B-cell precursor acute lymphoblastic leukemia and occur in more than 70% of BCR-ABL1 -positive and BCR-ABL1 -like cases of acute lymphoblastic leukemia. (haematologica.org)
  • Over the past few years, much has been learned about the tumor suppressive function of IKZF1 during leukemia development and the molecular pathways that relate to its impact on treatment outcome. (haematologica.org)
  • Gathering health information about patients with acute lymphoblastic leukemia may help doctors learn more about the disease and plan the best treatment. (clinicaltrials.gov)
  • Multiple-gated acquisition (MUGA) scans or echocardiograms are needed when the diagnosis of acute lymphoblastic leukemia (ALL) is confirmed, because many chemotherapeutic agents used in the treatment of acute leukemia are cardiotoxic. (medscape.com)
  • Assess the number of circulating clonal T cells at presentation and during thalidomide treatment. (bioportfolio.com)
  • It may also be offered when precursor lymphoblastic lymphoma comes back after treatment (recurs) or when it takes a long time to respond to treatment. (cancer.ca)
  • To describe health-related quality of life (HRQOL) reported by children and adolescents in responses to two interview questions during treatment for acute lymphoblastic leukemia (ALL) and compare their responses by age, gender, risk group, and time in treatment through a quantitative content analysis approach. (gwu.edu)
  • Despite risk-adapted treatment, survival of children with relapse of acute lymphoblastic leukemia (ALL) remains poor compared with that of patients with initial diagnosis of ALL. (uni-regensburg.de)
  • Leukemia-associated genetic alterations may provide novel prognostic factors to refine present relapse treatment strategies. (uni-regensburg.de)
  • CONCLUSIONS: Each leukemia subtype possesses specific telomere dysregulations that rely on phenotype, karyotype, response to treatment, and survival. (ac.be)
  • CAR T-cell therapy is a complex, multistep treatment. (ohsu.edu)
  • Treatment starts with collecting T cells from the patient's blood. (ohsu.edu)
  • Kymriah is approved for patients up to age 25 with B-cell precursor acute lymphoblastic leukemia that resisted treatment or came back after treatment (relapsed). (ohsu.edu)
  • Treatment of acute lymphoblastic leukemia. (nhi.no)
  • The incidence of allogeneic stem cell transplant will be analyzed. (clinicaltrials.gov)
  • Legionella bozemanii pulmonary abscess in a pediatric allogeneic stem cell transplant recipient. (biomedsearch.com)
  • 2. The method of claim 1, wherein said allogeneic anti-tumor T cell immune response further comprises at least about 5% circulating allogeneic type CD3 + T cells. (freepatentsonline.com)
  • However, its systemic inactivation in adult mice induces T-cell acute lymphoblastic lymphoma (T-ALL), a tumor type known to carry CIC mutations, albeit with low incidence. (sebbm.es)
  • Unlike systemic NHL in which the most com-mon cell lineage is B, cases of PCL are generally T-cell related. (scielo.br)
  • Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. (springer.com)
  • Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. (nhi.no)
  • A literature review yielded 105 patients with a diagnosis of precursor B-cell LYL based on less than 25% marrow involvement. (elsevier.com)
  • It is a neoplasm of precursor cells or lymphoblasts committed to either a B- or T-cell lineage. (hindawi.com)
  • It consists of the following subtypes: t(9;22)-BCR/ ABL t(v;11q23)-MLL rearrangement t(1;19)-E2A/PBX1 t(12;21)-ETV/ CBFα t(17;19)-E2A-HLF One interesting model of precursor B ALL shows aberrant function of a single gene, namely Pax5, as capable to change phenotype of B cells toward precursor cells. (wikipedia.org)
  • P. Early, H. Huang, M. Davis, K. Calame and L. Hood, An immunoglobulin heavy chain variable region gene is generated from three segments of DNA: V H ,D and J H , Cell , 19:981 (1980). (springer.com)
  • Gene rearrangements in T-cell lymphoblastic lymphoma . (acronymfinder.com)
  • The hybrid gene product ABL/BCR is an oncogene which could lead several types of leukemia including BAL. (wikipedia.org)
  • BCR/ABL induce cell adhesive and migratory abnormalities because the mutation will lead an abnormal response to chemokine SDF-1 MLL gene encode Histone-lysine N-methyltransferase (HRX), which is a histone methyltransferase. (wikipedia.org)
  • Immunohistochemistry provided objective confirmation of the coexistence of the 2 malignancies, as did molecular biology by revealing clonal T-cell receptor gamma and immunoglobulin heavy chain gene rearrangements. (semanticscholar.org)
  • Activation of the ABL tyrosine kinase is a primary event in the genesis of CML, as shown by the retrovirally mediated insertion of a human BCR-ABL gene into murine hematopoietic stem cells and the creation of BCR-ABL transgenic mice ( 3 ). (aacrjournals.org)
  • Within any normal population (sample) of T-cells, the cells and their gene rearrangement profiles are very diverse. (labtestsonline.org)
  • In lymphoma, the T-cells in affected tissue (such as blood, lymph node, or skin) are identical and their gene rearrangement profiles are likewise identical. (labtestsonline.org)
  • A T-cell receptor gene rearrangement test evaluates the T-cells in a person's sample to determine whether the majority of T-cell rearrangement profiles are diverse or identical. (labtestsonline.org)
  • It's also worth mentioning that medical oncologists deal mostly with solid tumors while hematologists specialize in cancers that involve blood disorders, such as leukemia. (vitals.com)
  • In most cancers, the abnormal cells grow to form a lump or mass called a tumor. (hopkinsmedicine.org)
  • CAR T-cell therapy, a type of immunotherapy, is a particular breakthrough for children with leukemia, and for adults with certain hard-to-treat blood cancers. (ohsu.edu)